跳到正文
EMA Scientific Guidelines·· 14 天前精选AI 评分65

EMA发布人用药品人类生殖与哺乳风险评估指南修订1草案并启动公众咨询

Draft guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product information - Revision 1

AI 导读

EMA的CHMP与PRAC于2026年11月3日通过并发布人用药品人类生殖与哺乳风险评估指南修订1草案(EMA/CHMP/PRAC/203927/2005 Rev.1),公众咨询自2026年11月9日起至2027年2月28日截止。

推荐理由

作为2005年版指南的修订草案,文件给出从数据到产品信息的风险评估流程并开放征求意见,便于对照现行版本定位变化。

正文 · 原文

PDF 文字版;图形和原始排版请参阅官方 PDF。

第 1 页

1   03 November 2026
2   EMA/CHMP/PRAC/203927/2005 Rev.1
3   Committee for Medicinal Products for Human Use (CHMP)
4   Pharmacovigilance Risk Assessment Committee (PRAC)




5   Guideline on risk assessment of medicinal products in
6   human reproduction and breastfeeding: from data to
7   product information
8   Draft
9

      Draft agreed by Committee for Medicinal Products for Human Use                            13 April 2026
      (CHMP); Pharmacovigilance Risk Assessment Committee (PRAC)

      Adopted by CHMP and PRAC for release for consultation                                     03 November 2026

      Start of public consultation                                                              09 November 2026

      End of consultation (deadline for comments)                                               28 February 2027

10

11   This guideline replaces “Guideline on Risk Assessment of Medicinal Products on Human Reproduction
12   and Lactation: from Data to Labelling (EMEA/CHMP/203927/2005)”
13
      Comments should be provided using this EUSurvey form. For any technical issues, please contact
      the EUSurvey Support.

14

      Keywords                    Pregnancy, lactation, breastfeeding, fertility, contraindication, risk
                                  minimisation,        non-clinical       assessment,        clinical      assessment,           risk
                                  assessment, Summary of Product Characteristics, Package Leaflet.

15

16




     Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
     Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
     Send us a question Go to www.ema.europa.eu/contact     Telephone +31 (0)88 781 6000       An agency of the European Union

     © European Medicines Agency, 2026. Reproduction is authorised provided the source is acknowledged.

第 2 页

17   Guideline on risk assessment of medicinal products in
18   human reproduction and breastfeeding: from data to
19   product information
20   Table of contents
21   Executive summary ................................................................................................. 4
22   1.    Introduction (background) .............................................................................. 5
23   2.    Scope ............................................................................................................... 5
24   3.    Legal basis and relevant guidelines .................................................................. 6
25   4. Non-clinical assessment of risk to human reproduction and development ....... 6
26   4.1. Introduction......................................................................................................... 6
27   4.1.1. Choice of species ............................................................................................... 7
28   4.1.2. New approach methods ...................................................................................... 7
29   4.1.3. Route of administration ...................................................................................... 7
30   4.1.4. Dose regimen/scheme ........................................................................................ 7
31   4.1.5. Pharmacokinetics/toxicokinetics .......................................................................... 8
32   4.1.6. Mechanism ....................................................................................................... 8
33   4.1.7. Multigenerational studies .................................................................................... 9
34   4.2. Evaluation process................................................................................................ 9
35   4.2.1. Uncertainties from available data ......................................................................... 9
36   4.2.2. No effect detected ............................................................................................. 9
37   4.2.3. Effects detected or known ................................................................................... 9
38   5. Clinical assessment of risk to human reproduction and development ............ 11
39   5.1. Introduction....................................................................................................... 11
40   5.2. Effects on fertility ............................................................................................... 11
41   5.3. Effects on pregnancy .......................................................................................... 12
42   5.3.1. Adverse pregnancy outcomes ............................................................................ 12
43   5.3.2. Clinical assessment of data on pregnancy outcomes............................................. 14
44   6.    Assessment regarding breastfeeding ............................................................. 17
45   6.1. Introduction....................................................................................................... 17
46   6.2. Risk assessment for a breastfed infant .................................................................. 17
47   6.2.1. Major elements of assessment: ......................................................................... 17
48   6.2.2. Complementary data for assessment: ................................................................ 18
49   6.3. Assessment of effect of a medicinal product on lactation (breastmilk production, secretion
50   and composition) ...................................................................................................... 18
51   6.4. Proteins including monoclonal antibodies and risk assessment for breastfeeding ........ 18
52   7.    Integration: From data to product information .............................................. 19
53   7.1. General principles ............................................................................................... 19
54   7.1.1. Fertility .......................................................................................................... 20
55   7.1.2. Pregnancy ...................................................................................................... 20


     Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
     information                                                                                                        Page 2/46
     EMA/CHMP/PRAC/203927/2005 Rev.1

第 3 页

56   7.1.3. Breastfeeding .................................................................................................. 22
57   7.2. Principles for recommendations ............................................................................ 23
58   7.2.1. Fertility .......................................................................................................... 23
59   7.2.2. Pregnancy ...................................................................................................... 23
60   7.2.3. Individuals of reproductive potential .................................................................. 25
61   7.2.4. Breastfeeding .................................................................................................. 26
62   8.    Reflections for the product information.......................................................... 27
63   8.1. Introduction....................................................................................................... 27
64   8.2. Summary of product characteristics (SmPC) .......................................................... 27
65   8.2.1. Section 4.6 of the SmPC ................................................................................... 28
66   8.2.2. Section 4.3 of the SmPC ................................................................................... 30
67   8.2.3. Section 4.4 of the SmPC ................................................................................... 30
68   8.2.4. Section 4.5 of the SmPC ................................................................................... 30
69   8.3. Package leaflet (PL) ............................................................................................ 30
70   9.    References ..................................................................................................... 32
71   Annex ................................................................................................................... 34
72




     Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
     information                                                                                                        Page 3/46
     EMA/CHMP/PRAC/203927/2005 Rev.1

第 4 页

73    Executive summary
74    Integrating non-clinical and human data to assess risks of medicinal products for human reproduction,
75    development and if used during breastfeeding is essential. Reflecting this assessment and subsequent
76    recommendations, in the product information of a medicinal product is also important to support
77    informed decisions by health care professionals and individuals using the medicinal product, and to
78    reduce adverse outcomes following use in these populations.

79    This is the first revision of the Guideline on Risk Assessment of Medicinal Products on Human
80    Reproduction and Lactation: from Data to Labelling. The main aim of this revision was to reflect
81    current standards regarding non-clinical - including the option for new approach methods (NAMs) - and
82    clinical assessments. The latter relate to different types of clinical studies, including
83    pharmacoepidemiologic studies, as well as other types of post marketing data. Further details on risk
84    classifications and how these impact recommendations for use of medicinal products during pregnancy,
85    in individuals of reproductive potential, and in breastfeeding are included. Examples of standard texts
86    (statements) for the Summary of Product Characteristics (SmPC) have been updated, and new
87    standard statements on fertility, as well as new standard texts for the Package Leaflet (PL) have been
88    added.

89    The guideline describes a stepwise process, starting with two sections on assessment of non-clinical
90    (section 4) and clinical data regarding human reproduction and development (section 5), followed by a
91    section on assessment of non-clinical and clinical data in relation to breastfeeding (section 6).
92    Thereafter, a section on integration of non-clinical and clinical data follows (section 7.1), which
93    describes general principles including classification of risks across areas, and provides guidance on
94    recommendations for use for each specific area (section 7.2). The guideline ends with a section on
95    reflections for the product information (section 8, both the SmPC, and PL) as well as an Annex
96    covering standardised texts for data description, recommendations and risk minimisation measures
97   in relation to pregnancy, individuals of reproductive potential and breastfeeding. Figure 1 describes the
98   structure of the guideline and the process it is intended to cover.

99   Figure 1. Stepwise process of risk assessment: from data to product information




100
101

      Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
      information                                                                                                        Page 4/46
      EMA/CHMP/PRAC/203927/2005 Rev.1

第 5 页

102       1. Introduction (background)
103   The information and recommendations on how to use a medicinal product in relation to human
104   reproduction, pregnancy or breastfeeding should enable health care professionals to manage different
105   circumstances, and support individuals in making informed decisions. These situations include
106   prescribing medicinal products to individuals of reproductive potential 1, or pregnant and breastfeeding
107   individuals. Therefore, the product information (PI), specifically the SmPC and PL, should present the
108   available evidence on identified and potential risks related to fertility, pregnancy, and breastfeeding,
109   together with recommendations on the use of the medicinal product in these populations as
110   appropriate, and on the management of risks in clinical practice.

111   Evaluation of effects on human fertility (male and female) frequently relies on findings from non-
112   clinical studies (reproductive toxicity studies and/or repeated dose toxicity studies), along with
113   knowledge on the mechanism of action and relevant clinical evidence of the active substance(s).

114   For pregnancy, the risk assessment is based on an integrated and continuous evaluation of clinical
115   experience and non-clinical toxicology, pharmacology and pharmacokinetic data.

116   During medicinal product development, and early post marketing period, non-clinical data are of great
117   importance since clinical experience is still lacking or limited in most clinical settings. In certain
118   situations, pregnant and/or breastfeeding individuals may be included in clinical trials [1], depending
119   on the medical condition being studied, as well as on the potential risk profile of the substance, or such
120   studies are undertaken with an aim to characterise use of a medicinal product in pregnant individuals.
121   Generally, clinical data becomes more abundant in the post marketing phase as real-world experience
122   with the medicinal product increases, and such data are essential to fully characterise safety in
123   humans. When formulating recommendations with respect to use in females of reproductive potential
124   and during pregnancy, the potential risk of adverse embryo-fetal or infant outcomes due to in utero
125   exposure should be weighed against the risk of not treating the pregnant individual.

126   For breastfeeding, the potential risk to the infant should be weighed against the known benefits of
127   breastfeeding itself. Risk assessment should preferably be based on human data, including
128   concentrations of the active substance (and/or metabolites) in breast milk, estimated exposure of the
129   breastfed infant, the toxicity profile of the substance and suspected adverse effects in breastfed
130   infants. Data on pharmacokinetic properties and certain non-clinical data can support the assessment.


131       2. Scope
132   This guideline applies to medicinal products for human use. The purpose of this guideline is to:

133   •   Describe the process for integrating non-clinical and clinical data, and to highlight key factors in
134       assessing the risk of adverse reproductive and developmental effects in humans. This includes
135       effects on fertility and on pregnancy, including effects on the embryo/fetus or child health following
136       exposure during pregnancy, and effects on the breastfed infant.

137   •   Outline how to describe available data, including potential or identified risks, and recommendations
138       for the use of a medicinal product, including relevant risk minimisation measures, in the SmPC and
139       the PL. Standard statements are provided.


      1 In this guideline, terminology relating to sex and gender is selected according to the context and population described.

      Sex-specific terms (e.g. female, male) are used where necessary for the understanding, such as fertility or for individuals of
      reproductive potential. Gender-neutral terms (e.g. individuals) are used when referring to those who are pregnant or
      breastfeeding. “Females of reproductive potential” refers to all females who are able to become pregnant, including
      adolescents. The term “individual” refers to a person using, or considering the use of, a medicinal product for treatment or
      prevention.

      Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
      information                                                                                                        Page 5/46
      EMA/CHMP/PRAC/203927/2005 Rev.1

第 6 页

140       3. Legal basis and relevant guidelines
141   This Guideline should be read in conjunction with the introduction and general principles of Annex I to
142   Directive 2001/83/EC, as amended, and all other relevant EU and ICH guidelines. These include, but
143   are not limited to:

144   •   Preclinical safety evaluation of biotechnology-derived pharmaceuticals
145       (EMA/CHMP/ICH/731268/1998 (ICH S6(R1))

146   •   Guideline on detection of reproductive and developmental toxicity for human pharmaceuticals
147       (EMA/CHMP/ICH/544278/1998 (ICH S5)
148   •   Guideline on genotoxicity testing and data interpretation for pharmaceuticals intended for human
149       use (EMA/CHMP/ICH/126642/2008 (ICH S2)
150   •   Toxicokinetics: A Guidance for Assessing Systemic Exposure in Toxicology Studies
151       (CPMP/ICH/384/95 (ICH S3A)).
152   •   Guideline on non-clinical testing for inadvertent germline transmission of gene transfer vectors
153       (EMEA/273974/2005)
154   •   SWP/NcWP recommendations on the duration of contraception following the end of treatment with
155       a genotoxic drug (EMA/CHMP/SWP/74077/2020)
156   •   ICH guideline M3(R2) on non-clinical safety studies for the conduct of human clinical trials and
157       marketing authorisation for pharmaceuticals (EMA/CPMP/ICH/286/1995)
158   •   ICH guideline M3 (R2) - questions and answers (EMA/CHMP/ICH/507008/2011)
159   •   Guideline on inclusion of pregnant and breastfeeding individuals in clinical trials
160       (EMA/CHMP/ICH/149462/2025 (ICH E21)
161   •   Guideline on good pharmacovigilance practices (GVP): Product- or population-specific
162       considerations III: Pregnant and breastfeeding women and their children exposed in utero or via
163       breastmilk (EMA/653036/2019)
164   •   Recommendations related to contraception and pregnancy testing in clinical trials, CTCG Clinical
165       Trials Coordination Group
166   •   GVP Module V – Risk management systems (EMA/838713/2011)
167   •   GVP Module XVI Addendum I – Risk minimisation measures for medicinal products with embryo-
168       fetal risks (EMA/608947/2021)
169   •   ENCePP Guide on Methodological Standards in Pharmacoepidemiology (EMA/95098/2010)
170   •   ENCePP Annex 2 to the Guide on Methodological Standards in Pharmacoepidemiology

171   •   Guideline on the Summary of Product Characteristics. Rules governing Medicinal products in the
172       European Community Volume 2C The Notice to Applicants


173       4. Non-clinical assessment of risk to human reproduction
174       and development

175   4.1. Introduction

176   Developmental and reproductive toxicity (DART) studies aim to detect effects of a medicinal product on
177   mammalian reproduction and development. They typically consist of a fertility and early embryonic
178   development (FEED) study, embryo-fetal development (EFD) studies in two species (rodent and non-
179   rodent), and a pre- and postnatal development (PPND) study. However, this standard approach may
180   be adapted according to various factors including the type of medicinal product, target population,
181   knowledge of pharmacological target(s) and its(their) role in reproduction and development.



      Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
      information                                                                                                        Page 6/46
      EMA/CHMP/PRAC/203927/2005 Rev.1

第 7 页

182   Results of other non-clinical studies and weight of evidence (WoE) approaches should also be
183   considered as they may significantly influence the testing strategy and/or risk assessment. See ICH
184   S5(R3) guideline [2] for further details on these aspects. Regarding risk assessment for breastfeeding,
185   see section 6.

186   For the non-clinical assessment, reproductive and developmental toxicity includes:

187   •   Effects on reproduction in the parental generation (i.e. fertility): any adverse effects (structural
188       and functional) on the male and/or female reproductive organs or on the related endocrine
189       systems including amongst others: gamete production and transport, reproductive cycle, mating
190       behaviour, or modification of other functions that are dependent on the integrity of the
191       reproductive system.

192   •   Effects on development in the progeny: any adverse effects (structural and functional) on the
193       conceptus resulting from prenatal exposure or induced during the suckling period or manifested
194       postnatally (adverse effects on e.g. behaviour and / or sexual maturation).


195   4.1.1. Choice of species

196   The rat is a common rodent species in all types of DART studies (FEED, EFD and PPND), whereas the
197   rabbit is a common non-rodent second species for the EFD study. For the EFD studies, at least one of
198   the selected species should be responsive to the primary pharmacodynamic effect of the medicinal
199   product. In addition, the pharmacokinetic profile, including biotransformation, should enable
200   assessment of the relevance of the species selected for DART testing and thus an extrapolation of the
201   results from animals to humans.

202   In cases where the rat or rabbit are considered unsuitable for testing due to e.g. lack of
203   pharmacological and/or pharmacokinetic relevance or tolerability issues, an alternative rodent or non-
204   rodent species should be considered. Other options including the use of genetically modified animals or
205   a species-specific surrogate molecule may also be considered provided that pharmacological relevance
206   is ensured. When no relevant species can be identified, the impact of this deficiency should be
207   discussed in the assessment report and considered for the recommendations in the SmPC and PL.


208   4.1.2. New approach methods

209   NAMs, including alternative in vitro, ex vivo, and non-mammalian in vivo assays may be valuable to
210   identify adverse effects or to contribute to the understanding of the mechanisms underlying
211   developmental and reproductive toxicity at any stage of medicinal product development. These
212   methods when qualified for context of use may also support risk assessment and, where justified,
213   reduce or replace certain in vivo studies. Further details are provided in the ICH S5(R3) guideline [2].


214   4.1.3. Route of administration

215   The route of administration used in DART studies should generally be the one intended for human use.
216   An alternative route may be acceptable if a similar or ‘better’ pharmacokinetic profile (i.e. resulting in
217   higher exposure) can be demonstrated.


218   4.1.4. Dose regimen/scheme

219   The dose range tested in DART studies should have covered a dose resulting in minimal maternal
220   toxicity such as e.g. decreased body weight or food consumption or, at the high dose, result in a 25-
221   fold exposure margin compared with the estimated human exposure at the maximum recommended

      Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
      information                                                                                                        Page 7/46
      EMA/CHMP/PRAC/203927/2005 Rev.1

第 8 页

222   dose. See ICH S5 guideline [2] for more details. While determining a “no observed adverse effect
223   level” (NOAEL) is desirable, dose levels should be chosen to reveal dose-related trends. Dose levels
224   leading to serious maternal and/ or offspring toxicity, including mortality, can mask a potential for
225   developmental toxicity.

226   It should be evaluated whether the applied dose intervals/frequencies achieve sufficient exposure
227   during the sensitive periods under study and are clinically relevant.


228   4.1.5. Pharmacokinetics/toxicokinetics

229   Exposure in pregnant animals to the active substance(s) and/or major human metabolite(s) (≥10%)
230   [2-5], should be assessed. Indirect estimation of exposure in pregnant animals, based on toxicokinetic
231   data from non-pregnant animals from the same species used in different repeated toxicity studies
232   represents an element of uncertainty.

233   When available, information regarding placental transfer of the active substance (and/or metabolites)
234   can be of value for the assessment.


235   4.1.6. Mechanism

236   Toxicants can disrupt reproduction and/or development through maternal/paternal toxicity, direct
237   effects on the conceptus (placenta, extraembryonic membranes, or embryo/fetus), indirectly via
238   maternally mediated effects, or a combination of both. Thus, substances not able to cross the placenta
239   can still cause embryo-fetal toxicity due to indirect alterations of maternal physiology (e.g.
240   hyperglycaemia).

241   If reproductive and/or developmental toxicity has been identified, an understanding of the molecular
242   basis (i.e. mechanism of action) to support a biologically plausible explanation for the observed
243   toxicity, together with interspecies comparisons of the pharmacological effect, is of value for risk
244   assessment. Mechanistic data can include information on pharmacokinetics, interactions with fertility
245   and developmental processes in the mother (hormonal disruption, cytotoxic effects, inhibition of
246   angiogenesis essential for ovarian function, placental development, embryonic growth), embryo/fetus
247   or extraembryonic tissues. Since medicinal products are often targeted towards a well-defined
248   biological entity (receptor, ion-channel, protein etc.), the on-target molecular interaction is usually
249   known. However, the actual embryo-fetal exposure, including time point for exposure in relation to the
250   sensitive period of development of a specific organ/tissue, will influence the final outcome.

251   A WoE evaluation (see section 4.2.) is an important part of human risk assessment since it is
252   acknowledged that it can be difficult to generate data in sufficient detail for a clear understanding of
253   both mode of action, and mechanism of action behind embryo-fetal toxicity, especially for a new
254   chemical entity from a new class, and within the remit of regulatory testing. This is due to the
255   complexity of normal development, a multitude of interaction points for a substance, and since mode
256   of action understanding involves several levels of biological organisation.

257   For gene therapies or vaccines using genetically modified viral vectors that are replication-
258   incompetent, the risk of vertical maternal and paternal germline transmission of vector DNA, should be
259   assessed. See Guideline on non-clinical testing for inadvertent germline transmission of gene transfer
260   vectors [6] for more details.

261   4.1.6.1. Genotoxicity

262   Results of comparative studies have shown that, in a qualitative sense, most germ cell mutagens are
263   likely to be detected as genotoxic in somatic cell tests. If positive genotoxic effects are identified in the

      Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
      information                                                                                                        Page 8/46
      EMA/CHMP/PRAC/203927/2005 Rev.1

第 9 页

264   genotoxicity battery tests (See ICH S2 [7]), this also raises concerns for reproductive and
265   developmental effects (both at gamete level as well as the embryo, depending on the exposure time).
266   See “Safety Working Party (SWP) recommendations on the duration of contraception following the end
267   of treatment with a genotoxic drug (EMA/CHMP/SWP/74077/2020)” [8] for further details.


268   4.1.7. Multigenerational studies

269   Reproductive studies evaluating drug-related effects over generations may be available in exceptional
270   circumstances. Particular attention should be paid to the robustness of the study design to meet the
271   study objectives driven by substance specific potential safety concerns. The clinical relevance of the
272   reported findings should be considered in the context of all other available non-clinical and clinical data
273   (including mechanistic studies).


274   4.2. Evaluation process

275   The non-clinical assessment should be based on all pharmacological (primary, secondary and safety),
276   pharmacokinetic and toxicological data available. In some situations, all elements from standard
277   reproductive toxicity testing may not be available or are not warranted. A WoE approach can in these
278   cases be adequate to support decision-making when evaluating reproductive and developmental risk.
279   Such approaches use the totality of evidence available, and take into account literature data, class
280   effect data and data from alternative models or NAMs such as (complex) in vitro models or in silico
281   models, as well as all available relevant non-clinical and clinical data for the substance. The severity of
282   the disease, therapeutic indication, the target population and other relevant risk factors should also be
283   taken into account.

284   In this context, WoE approaches are particularly useful to demonstrate presence of risk. However, if
285   the data are sufficiently robust and substantiated, a WoE evaluation to support the likelihood of
286   absence of risk can be accepted on a case-by-case basis.


287   4.2.1. Uncertainties from available data

288   The representativeness, completeness, strengths and weaknesses of available data sets should always
289   be considered in the evaluation process. If some non-clinical studies (including reproductive toxicity)
290   are lacking, or some studies are irrelevant, or if data on certain endpoints are lacking, the impact of
291   such insufficient data should be addressed in the evaluation and considered for the overall conclusion
292   on developmental and reproductive risk.


293   4.2.2. No effect detected

294   If appropriately designed developmental and reproductive toxicity studies with adequate systemic
295   exposure do not indicate direct or indirect harmful effects, and there are no relevant effects identified
296   in other pharmacological or toxicological studies, this conclusion enables finalisation of the non-clinical
297   evaluation process.

298   If no findings are observed for a substance belonging to a class where adverse effects are expected,
299   this may need further clarification.


300   4.2.3. Effects detected or known

301   If an effect suggesting reproductive and/or developmental toxicity is detected, the evaluation process
302   should continue as outlined below in order to assess the level of concern.

      Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
      information                                                                                                        Page 9/46
      EMA/CHMP/PRAC/203927/2005 Rev.1

第 10 页

303   There are several contributory elements that may affect the level of concern. The following aspects
304   should be taken into consideration:

305   4.2.3.1. General aspects

306   •   Recognition of an effect

307   Statistically significant differences between treatment and control groups alone do not necessarily
308   indicate a safety concern, nor does lack of statistical significance impute absence of an effect. Other
309   criteria of importance include biological plausibility, reproducibility, medicinal product- or species-
310   specific mode of action, relationship to an animal-specific metabolite, the magnitude and nature of the
311   effect and/or clear dose-response relationship. Furthermore, reproductive toxicity studies usually lack
312   statistical power to detect subtle increases in rare events. Thus, an increased frequency of rare events
313   in exposed animals in comparison with the study control as well as with recent historical control data
314   from the same strain and preferably from the laboratory in which the study was performed, may
315   increase the concern for reproductive toxicity in humans.

316   •   Inter-species concordance

317   Even if adverse findings from only one species can raise serious concerns, if similar effects are
318   observed in more than one species, it may increase the concern for developmental and/or reproductive
319   toxicity in humans. Inter-species concordance is most likely to be identified for structural birth
320   defects/congenital anomalies, or histopathological examinations of reproductive organs, because these
321   endpoints are studied in multiple species.

322   •   Type of effects

323   Structural birth defects/malformations and embryo-fetal lethality have more weight in estimating a
324   concern for developmental toxicity in humans, than general effects (e.g. growth retardation and
325   variations, as delays in ossification). The latter, possibly reversible effect(s), might be induced by
326   maternal stress or other maternal toxicity.

327   Data from reproductive toxicity studies and/or from repeated dose toxicity studies in sexually mature
328   animals may suggest detrimental effects on fertility. In repeated dose toxicity studies, such effects
329   could be alterations to endocrine function or histopathological changes in the gonads or genital organs,
330   which may be detected in both rodents and non-rodents. Further understanding of possible
331   mechanisms is desirable for risk assessment.

332   •   Multiplicity of effects

333   Multiplicity of effects usually increases concern for reproductive toxicity in humans. Multiplicity refers to
334   the observation, in a single species or animal model, of two or more effects with related biological
335   endpoints in fetal examinations, e.g. abnormally shaped vertebrae plus abnormal number of vertebrae
336   would give rise to increased concern, more than just a single observation with regards to vertebral
337   development.

338   •   Adverse effects at various stages of the reproductive process

339   This refers to observations in a single species or animal model, of effects during different stages of the
340   reproductive process, e.g. increased early intrauterine death plus some malformations would give rise
341   to increased concern with regards to developmental toxicity.

342   •   Maternal toxicity

343   If developmental toxicity is seen only at maternally toxic dose levels, further understanding of
344   potential causality between maternal and developmental toxicity is desirable. From a regulatory

      Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
      information                                                                                                        Page 10/46
      EMA/CHMP/PRAC/203927/2005 Rev.1

第 11 页

345   perspective, claims that developmental toxicity is due to maternal toxicity should be adequately
346   justified. Further, there needs to be support that such findings do not have clinical relevance (e.g., by
347   providing mechanistic data in support of maternal toxicity being the reason for the observed
348   developmental toxicity).

349   4.2.3.2. Specific aspects

350   •   Animal to human exposure ratio

351   This should be based on the systemic exposure of the animal at the NOAEL for reproductive toxicity
352   and the systemic exposure in human at the maximum therapeutic dose. In case of serious embryo-
353   fetal outcomes in the animal studies, estimations of animal and human exposure ratios at doses
354   associated with malformation or embryo-fetal lethality can provide further insight for the risk
355   assessment.

356   When reporting animal data in SmPC section 4.6, a tiered system on how to interpret NOAEL for EFD
357   toxicity testing should be taken into account [2]. In general, there is increased concern when the
358   NOAEL occurs at exposures less than 10-fold the human exposure at the maximum recommended
359   dose. Above this threshold, concern is reduced, and effects observed at 25-fold or larger exposure
360   margins are usually of minor concern for clinical use.

361   •   Neurodevelopmental risk assessment

362   The entire nervous system, including the central nervous system (CNS) undergoes continuous complex
363   multifactorial development from early embryogenesis through to adulthood. From a non-clinical
364   perspective, the risk assessment should take into account the totality of available evidence namely
365   pharmacology, pharmacokinetics and toxicology data. Nevertheless, non-clinical models may not fully
366   reflect the complexity of human neurodevelopment, which needs to be considered in the assessment.
367   In particular, the clinical relevance of finding(s) from neurobehavioral tests conducted in the PPND
368   studies, should be thoroughly interpreted in combination with the overall human risk assessment.


369       5. Clinical assessment of risk to human reproduction and
370       development

371   5.1. Introduction

372   The clinical assessment will generally be based on various types of clinical data. These could include
373   case reports, case series, clinical trials, and epidemiological studies and originate from different
374   sources, e.g. electronic healthcare records, pregnancy registries, registries of congenital anomalies,
375   and spontaneously reported post-marketing data.

376   The assessment should consider the scientific quality and robustness of available data, methodology
377   for data collection, study designs, the clinical context such as target population, and the amount of
378   available data.


379   5.2. Effects on fertility

380   Fertility refers to the ability of an individual (male or female), a couple, or a population to reproduce.
381   Infertility is defined as a disease of the male or female reproductive system characterized by the failure
382   to achieve a clinical pregnancy after one year or more of regular unprotected sexual intercourse [9].
383   Clinical evaluations of fertility typically focus on couples who meet this criterion.




      Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
      information                                                                                                        Page 11/46
      EMA/CHMP/PRAC/203927/2005 Rev.1

第 12 页

384   Medicinal products may impair fertility of males and/ or females, through various mechanisms such as
385   hormonal disruption or cytotoxic effects. Effects may be reversible or permanent. The pharmacological
386   properties of the medicinal product, together with the characteristics of the target population, will
387   guide the most appropriate approach to assessing potential adverse effects on fertility.

388   Evaluation of fertility may include, but is not limited to, assessing effects on hypothalamic/pituitary
389   gonadal function, as well as effects on the reproductive organs/tissues. In addition, impairment of
390   implantation or an increased occurrence of early spontaneous abortion, are other relevant fertility
391   markers. Surrogate markers of fertility may be appropriate and can be studied on a case-by-case
392   basis. Studying effects on fertility by monitoring reproductive outcome in couples is generally
393   considered difficult due to practical and methodological challenges.


394   5.3. Effects on pregnancy

395   5.3.1. Adverse pregnancy outcomes

396   The administration of a medicinal product during pregnancy may cause various adverse effects in the
397   (unborn) child, including morphological, and/or functional developmental disturbance in the embryo or
398   fetus - whether detected at birth or not – as well as embryonic or fetal death. The nature and severity
399   of these effects depend on different factors including timing of exposure during critical phases of
400   development. Also, the maternal disease being treated may in itself affect embryo/fetal development
401   adversely, which needs to be taken into account.

402   Main types of adverse pregnancy outcomes include:

403   •   Non-live birth, including spontaneous abortion (miscarriage) and fetal death

404   •   Congenital malformation

405   •   Embryotoxic and/or fetotoxic effects

406   •   Neonatal outcomes

407   •   Neurodevelopmental disorders (NDD)

408   In addition, some effects fall outside these categories (e.g. transplacental carcinogenesis). For detailed
409   description/definition of “susceptible periods” and “adverse pregnancy outcomes” see “Guideline on
410   good pharmacovigilance practices (GVP) Product- and Population- Specific Considerations III: Pregnant
411   and breastfeeding women and their children exposed in utero or via breastmilk” [10].

412   5.3.1.1. Non-live birth, including spontaneous abortion (miscarriage) and fetal death

413   Non-live births include spontaneous abortion/miscarriage (early fetal death, that occurs before 20
414   completed weeks of gestation), stillbirth (late fetal death, that occurs after 20 completed weeks of
415   gestation). Also, termination of pregnancy due to embryo-fetal abnormalities is included in this group
416   of events. Incomplete capture of early pregnancies because pregnancies may not be immediately
417   recognised makes precise estimation of spontaneous abortion frequencies uncertain but is about 25%
418   of all pregnancies. This frequency increases with maternal age. Stillbirths are reported to occur in
419   about 0.3% of total births in Europe (range: 1.8-4.7 per 1000) [11].




      Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
      information                                                                                                        Page 12/46
      EMA/CHMP/PRAC/203927/2005 Rev.1

第 13 页

420   5.3.1.2. Congenital malformation (birth defects)

421   Congenital malformation 2 are structural anomalies of organs, systems, or parts of the body that occurs
422   during intrauterine development and may be associated with altered organ or system function. A
423   congenital malformation may result from genetic factors or from exposures to an environmental factor
424   including medicinal products. Congenital malformations can have significant medical, surgical, or
425   cosmetic consequences.

426   While it may be possible to diagnose some congenital malformations prenatally, others will only be
427   captured during the first years of life, leading to higher prevalences with longer follow-up after birth.
428   Additionally, in studies restricted to live births, risks may be underestimated if the medicinal product
429   caused pregnancy losses (i.e. live-birth bias, see [12,13]), or if the pregnancy is terminated due to
430   major malformations detected in utero. Prevalence also varies depending on how major malformations
431   are defined in the data source. In Europe, the EUROCAT classification system provides a harmonised
432   framework for categorizing congenital malformations across data sources, assigning major or minor
433   status to specific conditions within organ systems [14]. Additional factors, such as the inclusion or
434   exclusion of minor malformations or those due to genetic diseases, will also impact reported
435   prevalence. Prevalence estimates may also differ depending on whether exposure information is
436   collected prospectively (before pregnancy outcome is known, either adverse or non-adverse) or
437   retrospectively (after the outcome), the latter being more susceptible to recall bias. The live birth
438   prevalence of major congenital malformations is reported to be 2–4% in Europe [14] and 3-5% in the
439   United States [15].

440   5.3.1.3. Embryotoxic and/or fetotoxic effects

441   Embryotoxic and/or fetotoxic effects include impaired fetal growth (low/very low birth weight, small for
442   gestational age or intrauterine growth restriction), excessive growth (large for gestational age or fetal
443   macrosomia), and adverse effects on organs (e.g., endocrine or reproductive organs). Embryotoxicity
444   refers to effects from exposure during the first trimester, while fetotoxicity generally refers to exposure
445   in the second and/or third trimester.

446   5.3.1.4. Adverse neonatal outcomes

447   Adverse neonatal outcomes generally reflect pharmacological effects of the medicinal product during
448   late pregnancy or around the time of delivery, while preterm births, neonatal and infant death also can
449   belong to this category. For example, exposure to immunomodulating or immunosuppressive
450   substances may increase the risk of infections in the newborn. Other examples include neonatal
451   withdrawal syndrome resulting from sudden discontinuation of exposure to a medicinal product (e.g.
452   opioids), or persistent pulmonary hypertension of the newborn (PPHN), following exposure to
453   serotonergic or vasoconstrictive substances. The likelihood and severity of these effects depend on the
454   pharmacological properties of the substance, the timing, degree and duration of exposure, and the
455   developmental stage at which the fetus is exposed.

456   5.3.1.5. Neurodevelopmental disorders (NDD)

457   The entire nervous system, including the CNS, remains vulnerable to neurotoxic effects throughout
458   pregnancy. Accordingly, in utero exposure to medicinal products may impact on neurodevelopment,
459   even in the absence of structural anomalies. A consensus definition of NDD is not available, however
460   the International Classification of Diseases ICD-11 [16] defines NDD as behavioural and cognitive
461   disorders with onset during the developmental period before 18 years of age, impairing intellectual,

      2 Congenital malformation - narrow subset of congenital anomaly - is used for errors in morphogenesis excluding

      disruptions or deformations. Birth defect refers to the observable structural anomalies that are present at birth (GVP
      Product- or Population-Specific Considerations III: Pregnant and breastfeeding women and their children exposed in utero
      or via breastmilk [10])

      Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
      information                                                                                                        Page 13/46
      EMA/CHMP/PRAC/203927/2005 Rev.1

第 14 页

462   motor, language, or social functions. Examples include intellectual disability, autism spectrum disorder
463   (ASD), attention-deficit/hyperactivity disorder (ADHD), and learning disorders. These outcomes are
464   important considerations in the long-term safety assessment of medicinal products used during
465   pregnancy.

466   Risk assessment of NDDs following prenatal medicinal product exposure typically relies on human
467   observational studies, as non-clinical models may not fully reflect the complexity of human
468   neurodevelopment. Such studies should use validated measures to assess neurodevelopment, and
469   different types of NDDs should be analysed separately. Combining heterogeneous conditions (e.g.
470   ADHD, ASD, intellectual disability, and learning disorders) into a single composite outcome is
471   problematic because they differ in aetiology, developmental course, and measurement, which can
472   distort risk estimates and obscure clinically meaningful, condition-specific effects. Further, given the
473   potential for delayed diagnosis of exposure-related NDDs, sufficient follow-up periods to detect
474   outcomes that may only emerge later in childhood are needed. The minimum follow-up period should
475   preferably exceed the upper quartile of the median age at diagnosis, i.e. the age by which
476   approximately 75% of affected children have been diagnosed, in the relevant country or setting. Study
477   designs must also account for the multifactorial nature of NDDs and the role of maternal, paternal and
478   child covariates, including relevant environmental factors, in the relationship with the exposure of
479   interest, and control for potential confounders to ensure the reliability and interpretability of results.
480   Consideration as to the role of different methods of ascertainment in geographical or temporal
481   differences in rates of NDD may also be warranted. As a consensus definition for NDD is not available,
482   particular attention should be given to the definition of NDD and its components in any given study or
483   data source.


484   5.3.2. Clinical assessment of data on pregnancy outcomes

485   For clinical assessment of outcomes of exposure to a medicinal product during pregnancy, available
486   sources of evidence are often non-interventional. However, in certain situations, pregnant individuals
487   may be included in clinical trials [1], depending on the medical condition being studied, as well as on
488   the potential risk profile of the substance, or such studies are undertaken with an aim to characterise
489   use of a medicinal product in pregnant individuals. Evaluation of clinical trials follows standard
490   methodology, as appropriate for the specific trial.

491   Given the variation in background prevalence for adverse pregnancy outcomes, and methodologies
492   across data sources and studies, using an appropriate control group from the same data source, as
493   well as similar duration of follow up, is desirable, and should be aimed for, if feasible, to facilitate valid
494   comparisons and a fulsome assessment.

495   For non-interventional pregnancy studies, several common biases need to be considered [12,13].
496   These issues can distort results but can, at least to a certain extent, be addressed through careful
497   study design, appropriate timing definitions, and sensitivity analyses as outlined below:

498   Ascertainment of exposure to the medicinal product in pregnancy:

499   •   Spontaneous and solicited reports may be reported prospectively, in which exposure to the
500       medicinal product is reported before the pregnancy outcome is known, either adverse or non-
501       adverse and prior to any prenatal investigation. In contrast, retrospective reports involve cases
502       where exposure is reported after the outcome is already known. While retrospectively reported
503       pregnancies should not be excluded from the assessment, an analysis restricted to prospectively
504       reported pregnancies avoids recall bias.




      Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
      information                                                                                                        Page 14/46
      EMA/CHMP/PRAC/203927/2005 Rev.1

第 15 页

505   •   Timing and degree of exposure to the medicinal product during pregnancy relative to susceptible
506       periods should be considered. For instance, where pregnancies are exposed late in the first
507       trimester, organogenesis may have already been completed and their capture as exposed
508       pregnancies may bias a harmful effect towards the null. Pharmacokinetics including half-life and
509       placental transfer should be considered in relation to degree of exposure during pregnancy.
510       Furthermore, if exposure occurred prior to conception or the susceptible period for a particular
511       adverse outcome, these parameters have to be considered before excluding exposure to the
512       medicinal product as relevant to the adverse pregnancy outcome of interest.

513   •   When comparing adverse pregnancy outcomes following exposure to a medicinal product which
514       occurs after conception with those among pregnancies without such exposure, immortal time bias
515       may occur:

516       −    either when the unexposed ‘immortal’ (event-free) time spent prior to exposure is incorrectly
517            classified as exposed, leading to underestimated risk among the exposed pregnancies,

518       −    or the unexposed ‘immortal’ time prior to exposure is incorrectly excluded from the analysis,
519            leading to an over-estimated risk among unexposed pregnancies and selection bias
520            (pregnancies included in the exposed cohort had to survive without experiencing the adverse
521            pregnancy outcome in order to be exposed to the medicinal product and therefore may differ
522            from those that were never exposed).

523       This can be avoided by defining cohort entry at treatment initiation or by using a time-varying
524       exposure definition. Alternatively, a landmark design (e.g., gestational week 12 or 20) may be
525       used, although this can introduce live birth bias by excluding early pregnancy losses.

526   Ascertainment of the adverse pregnancy outcome:

527   •   The definition of the adverse pregnancy outcome studied, should be considered. Caution is advised
528       in generalising conclusions to subtypes of outcomes or components of a composite outcome not
529       explicitly studied. Population-based studies in real-world data sources may be affected by
530       misclassification, for example due to reliance on a single (diagnostic) code that does not confirm
531       the outcome, overrepresentation of more severe outcomes (e.g. conditions requiring
532       hospitalisation), or underrepresentation of outcomes that may not routinely present to the
533       healthcare system (e.g. early miscarriage, pregnancy termination, or certain minor congenital
534       anomalies).

535   •   The period of follow-up may have important implications. Prevalence of major anomalies increases
536       when infants are followed to 12 months of age rather than being evaluated at birth only. In the
537       context of NDDs, assessing CNS function in early childhood present challenges, as some disorders
538       may not manifest until later in childhood, thereby requiring years of follow up to capture
539       adequately.

540   Selection bias:

541   Selection bias in studies of medicinal products exposure during pregnancy can occur when the
542   pregnancies included are not representative of pregnancies in general. This can arise in several ways.
543   For example, left truncation occurs when pregnancies are not observed from conception and need to
544   reach a certain gestational age to be captured in a data source, leading to under-ascertainment of the
545   total number of pregnancies. Live birth bias is another concern and occurs when studies include only
546   live-born infants, potentially underestimating risk if the exposure leads to pregnancy losses that are
547   excluded from analysis. This issue is less relevant in studies of long-term outcomes such as NDDs,
548   which are assessed among live births only. Avoiding selection bias requires careful attention to


      Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
      information                                                                                                        Page 15/46
      EMA/CHMP/PRAC/203927/2005 Rev.1

第 16 页

549   inclusion criteria, timing of data capture, and completeness of outcome reporting, especially for early
550   pregnancy losses and non-live births.

551   Confounding bias:

552   •   Minimising confounding by indication in pregnancy safety studies requires careful study design,
553       particularly in comparator selection and adjustment for disease-related factors. Restricting the
554       study population to pregnant individuals with the same underlying condition—for example, by
555       including a non-medicated disease comparison group—can help control for confounding at the
556       design stage. However, confounding by disease severity may still remain. To address this,
557       researchers can use an active comparator group (e.g. pregnant individuals treated with alternative
558       treatment for the same indication) and apply statistical adjustment for available markers of disease
559       severity and other confounders to strengthen causal inference. Designs where siblings in
560       unexposed and exposed pregnancies are compared may also be helpful.

561   •   Confounding may also arise due to differences between exposed and comparator cohorts in the
562       calendar period over which pregnancies occurred (due to changes in prescribing practices or
563       outcome detection over time) or gestational age over which pregnancies were observed (whereby
564       the cohort observed from an earlier gestational age may be less susceptible to left truncation) and
565       should be addressed.

566   •   The potential causal relationship addressed by the research question including relevant maternal,
567       paternal and offspring covariates, and biological (including the indication) as well as environmental
568       factors should be carefully considered. This should include in particular the impact of unmeasured
569       confounding. It is also important to consider over-adjustment bias and collider (selection) bias that
570       could arise due to adjustment for intermediate covariates occurring or measured during or at the
571       end of pregnancy and after the exposure. Evaluation should be informed by clinical knowledge and
572       relevant literature and may be complemented by causal diagrams.

573   Required sample size:

574   There is no predefined number of exposed pregnancies that is sufficient for a reassuring conclusion for
575   any potential risk to the embryo or fetus as this depends on the baseline rate of a particular adverse
576   outcome, and the many factors that influence its detection and reporting. For major congenital
577   malformations (with baseline rates of 3-5%), a few hundred prospectively collected exposed
578   pregnancies, with known outcomes, without a concerning pattern are generally needed to conclude
579   that a manyfold increased risk is less likely.

580   For stronger reassurance, including lack of increased risk for major congenital malformations in specific
581   organs, data of adequate quality from a few thousand prospectively collected exposed pregnancies,
582   with known outcomes not indicating an increased risk are needed.

583   For some adverse pregnancy outcomes, where the background rates are more common than for major
584   congenital malformations, smaller sample sizes may suffice.

585   Observations from different data sources can be pooled provided methodological considerations are
586   considered, for instance use of comparable definitions for the outcomes of interest. The estimated
587   absolute frequency, relative risk or excess risk of an adverse pregnancy outcome following exposure to
588   the medicinal product in utero should in general be presented with a confidence interval, where the
589   width of the interval reflects the precision of the estimate.




      Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
      information                                                                                                        Page 16/46
      EMA/CHMP/PRAC/203927/2005 Rev.1

第 17 页

590       6. Assessment regarding breastfeeding

591   6.1. Introduction

592   Clinical data are essential for characterising safety of a medicinal product for a breastfed infant, and to
593   support recommendations regarding treatment of the mother during breastfeeding. Non-clinical data
594   can be complementary, particularly when clinical data are limited. Milk samples collected from
595   lactating 3 or breastfeeding individuals can be used in studies to quantify medicinal product transfer
596   into human milk, allowing calculation of the relative 4 and/or daily 5 infant dose.

597   Pharmacokinetics of the medicinal product, in both mother and infant should also be considered. This
598   does not only cover possible transfer into breast milk, but also systemic exposure in the infant (based
599   on intestinal absorption, distribution, metabolism and elimination). Additionally, the pharmacodynamic
600   properties of the medicinal product should also be considered to assess the potential for adverse
601   reactions in the infant during breastfeeding.

602   Data from follow-up of breastfed infants for potential adverse reactions provides additional valuable
603   insights into the safety of medicinal products during breastfeeding.

604   Modelling and simulation approaches can be used to leverage sparse human data, primarily through
605   population pharmacokinetic modelling. Physiologically based pharmacokinetic modelling (PBPK) needs
606   qualified models, however since the pharmacokinetics of transfer to breast milk is a complex process
607   and the impact of the model will be high, the feasibility of using such models is currently limited.

608   Complementary role of non-clinical data

609   Information regarding excretion into animal milk of the active substance (and/or metabolites) can be
610   of value for the assessment. However, due to interspecies differences in lactation physiology and milk
611   composition, direct quantitative extrapolation of medicinal product concentrations in animal milk to
612   human milk is generally not possible. Non-clinical data alone is generally insufficient to support
613   definitive recommendations in humans, unless the method or model is predictive for human milk
614   transfer or infant exposure/safety in the context of use. In general, recommendations on breastfeeding
615   should be based primarily on human data, while non-clinical data may contribute to risk assessment
616   when adequate human data are lacking, and should be interpreted with caution.


617   6.2. Risk assessment for a breastfed infant

618   Major and complementary factors for risk assessment are described below. Their order below does not
619   reflect their relative importance in the assessment process.


620   6.2.1. Major elements of assessment:

621   •   Breastfed infants’ plasma/blood concentrations of the medicinal product, which support direct
622       estimation of systemic exposure.


      3
        “Lactating” refers to the physiological production of milk, while “breastfeeding” refers to the act of feeding the infant. In
      some cases, milk samples may still be collected after breastfeeding has ceased if milk production persists.
      4
        Relative infant dose (RID) is the estimated daily dose of a medicinal product received by an infant through breast milk
      (mg/kg/day), expressed as a percentage of the maternal weight-adjusted dose (mg/kg/day). It provides an estimate of the
      extent of medicinal product transfer into breast milk. For quantification of risk for the infant based on RID categories see
      section 8.2.1.2.
      5 Daily infant dose (DID) is the absolute dose of a medicinal product ingested by an infant through breast milk. It provides a

      direct measure of infant medicinal product exposure during breastfeeding. DID can be compared with the therapeutic daily
      dose for an infant of the same age and body weight receiving the medicinal product as treatment.


      Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
      information                                                                                                        Page 17/46
      EMA/CHMP/PRAC/203927/2005 Rev.1

第 18 页

623   •   Estimation of the amount of medicinal product received by infants through breast milk, based on
624       the measured concentration of the active substance /metabolite(s) in human milk, taking into
625       account maternal dose and treatment duration, as well as estimated breastmilk intake by the
626       infant. These could be expressed as a relative infant dose (RID) or a daily infant dose (DID).

627   •   Case reports of adverse effects in breastfed infants, which could be signals of potential safety
628       concerns.

629   •   Follow up of breastfed infants during their mothers’ treatment, which supports ongoing safety
630       evaluation and could potentially identify both short-term and long-term effects.

631   •   Pharmacokinetics in the mother (considering route of administration, plasma concentrations and
632       elimination characteristics), in breast milk and in the infant (particularly gastrointestinal absorption
633       and rate of elimination).

634   •   Pharmacodynamic properties and safety profile of the medicinal product, including known class
635       effects and/or data from paediatric use.


636   6.2.2. Complementary data for assessment:

637   As major elements of assessment are usually scarce, all complementary data available should be
638   assessed as well.

639   •   The physicochemical properties of the medicinal product, which help estimate the extent of its
640       transfer into breast milk.

641   •   Documented use of the medicinal product during breastfeeding, even without formal follow up of
642       breastfed infants.

643   •   Infant-specific factors, such as age, overall health status and developmental maturity.

644   •   Non-clinical data (e.g., qualified in vitro or in silico methods, transfer of the medicinal product in
645       animal milk, peri- and post-natal or juvenile toxicity studies) which can support estimation of
646       exposure and risk.

647   A pharmacological class effect might not always be relevant for risk assessment for breastfeeding
648   infants, as infant exposure can vary substantially between substances within the same class due to
649   differences in their pharmacokinetic properties, leading to differences in risk classification.

650   Risks from direct dermal exposure to the breastfed child, when there is topical application on the
651   breast or on large skin area should be considered.


652   6.3. Assessment of effect of a medicinal product on lactation (breastmilk
653   production, secretion and composition)

654   Some medicinal products can decrease or increase breast milk production by affecting prolactin levels.
655   Others can affect breast milk secretion by affecting oxytocin levels. Additionally, certain medicinal
656   products may impact the composition or quality of breast milk, or other aspects related to
657   breastfeeding. All existing data on these effects should be considered when relevant.


658   6.4. Proteins including monoclonal antibodies and risk assessment for
659   breastfeeding

660   Physiological processes (including increased paracellular permeability of the mammary epithelium
661   shortly after delivery) result in therapeutic monoclonal antibodies (mAbs) being present in higher

      Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
      information                                                                                                        Page 18/46
      EMA/CHMP/PRAC/203927/2005 Rev.1

第 19 页

662   amounts in the colostrum than in mature milk, with rapidly decreasing levels of the mAb thereafter.
663   Gastrointestinal uptake of mAbs by the breastfed infant is also very low, with some possible exception
664   for preterm infants and neonates. Due to intrinsic properties, mAbs are denatured and rendered
665   inactive following acidification in the infant’s stomach, further limiting systemic exposure.

666   A standard recommendation cannot be given for all mAbs, as safety during breastfeeding depends on
667   substance-specific factors including the extent of breast-milk transfer, the infant’s gastrointestinal
668   absorption and the pharmacological mechanism of the mAb. Furthermore, findings from (enhanced)
669   (e)PPND studies, if appropriate (see [2,17,18]), should be considered. However, when the risk profile
670   of the mAb is sufficiently characterised, product-specific recommendations can be made. In some
671   cases, it may be appropriate to restrict breastfeeding only right after birth and to permit breastfeeding,
672   thereafter, based on physiological principles and inherent characteristics of the medicinal product. A
673   similar case-by-case approach may be applicable to other protein-based therapeutics. Standard texts
674   for mAbs or protein-based products with respect to breastfeeding are included in the Annex.


675       7. Integration: From data to product information

676   7.1. General principles

677   The general aim of this section is to guide on how to integrate data from various sources to determine
678   appropriate wording for the SmPC and PL in relation to male and female fertility, for females of
679   reproductive potential, and for pregnant or breastfeeding individuals. Efforts should be made to
680   provide the reasons for the recommendations given. This information is important for the health care
681   professional and for the (to be) treated individual to support an informed decision.

682   In the overall assessment, available knowledge from all relevant data sources should be considered.
683   This includes clinical experience, pharmacological activity, pharmacokinetic data, results from non-
684   clinical studies, and knowledge about medicinal products within the same class; based on information
685   from e.g. clinical studies (interventional or non-interventional), non-clinical testing (in vitro or in vivo),
686   spontaneous reporting as well as literature. Aspects such as alternative treatments, impact of the
687   maternal disease on the pregnancy, and clinical practices should also be considered. The more
688   extensive clinical data being available, the less emphasis is put on non-clinical studies in the
689   integration process.

690   Within each specific area, following an integrated assessment of available evidence and its strengths
691   and limitations, a general risk classification is concluded upon, as follows.

692   •   A risk is considered identified if there is sufficient scientific evidence from non-clinical and/or
693       clinical data, and in some instances taking pharmacodynamic effects into account, to conclude,
694       with at least a reasonable possibility, that the adverse outcome is caused by the medicinal
695       product.
696   •   A risk is considered potential if scientific evidence from non-clinical and/or clinical data, and in
697       some instances taking pharmacodynamic effects into account, suggests a possible causal
698       relationship between the adverse outcome and the medicinal product. It can also correspond to
699       insufficient non-clinical and/or clinical data, but where available data raise concerns.
700   •   A risk is considered unlikely when a sufficiently large amount of non-clinical and / or clinical data
701       of adequate quality, including knowledge of the pharmacodynamic effects, do not raise concerns
702       for adverse outcomes.
703   •   Available data do not raise specific concerns but are insufficient to draw final conclusions.




      Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
      information                                                                                                        Page 19/46
      EMA/CHMP/PRAC/203927/2005 Rev.1

第 20 页

704   This overall assessment guides the information, and recommendations, including risk minimisation
705   measures, to be included into the SmPC and PL. The risk classification can also guide risk management
706   planning, as outlined in GVP Module V on Risk management systems [19]. Some guiding elements
707   regarding the risk classification within each specific area are presented below.

708   The PI, and if appropriate, the recommendations for use in these different populations, should be
709   updated when relevant new data become available.


710   7.1.1. Fertility

711   The evaluation of effects on human fertility mostly relies on the outcome of non-clinical studies and
712   knowledge of any effect that could be related to the mechanism of action. If available, clinical data
713   should be integrated in the assessment. Regarding non-clinical studies, the assessment should be
714   based on the results of genotoxicity studies, FEED studies and/or repeat-dose toxicity studies. The
715   latter generally provides important information contributing to further characterise potential effects on
716   fertility based on pathology and functional parameters for both male and female reproductive function.

717   Evidence of impaired fertility includes abnormal sperm parameters, menstrual or ovulatory
718   disturbances, testicular or ovarian toxicity, reduced conception rates in animals, and additional
719   mechanistic evidence regarding reproductive hormones or germ cell function.

720   For the assessment of the risk classification, some guiding elements are outlined below:

721   7.1.1.1. Identified risk for impaired fertility

722   •   Non-clinical data of human relevance and of sufficient quality, and / or clinical data of sufficient
723       quality show a risk for impaired fertility.
724   •   A plausible mechanism of action has been identified that leads to risk for impaired fertility.

725   7.1.1.2. Potential risk for impaired fertility

726   •   Non-clinical data suggest adverse effects on fertility, but human relevance is uncertain, and there
727       is no or insufficient clinical evidence to conclude causality.

728   7.1.1.3. Unlikely risk for impaired fertility

729   •   Non-clinical data do not show or suggest impaired fertility and there is no clinical evidence
730       suggesting adverse effects on fertility.

731   7.1.1.4. Insufficient data with respect to fertility

732   •   Available data do not raise specific concerns but are insufficient to draw final conclusions e.g. non-
733       clinical findings are inconclusive, and clinical evidence is insufficient to fully assess risk of adverse
734       effects on fertility.

735   7.1.2. Pregnancy
736   An integrated approach for risk assessment of prenatal exposure and adverse pregnancy outcomes is
737   presented below, in the form of questions adapted from teratological principles [20-22], modern
738   epidemiological reasoning and principles for assessment of medicinal products safety in pregnancy. The
739   order of questions below does not reflect the relative importance of these in the assessment process.

740   While the reliability of the overall assessment will depend on the extent to which clear and definitive
741   answers to these questions can be obtained, in practice conclusions may need to be drawn
742   acknowledging that at the time of the assessment some of these questions remain unanswered.



      Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
      information                                                                                                        Page 20/46
      EMA/CHMP/PRAC/203927/2005 Rev.1

第 21 页

743   7.1.2.1. Integrated questions for risk assessment of causation between prenatal exposure
744   and adverse pregnancy outcomes

745   1.       Exposure Timing: Was there documented exposure to the medicinal product at critical times
746   during prenatal development, and does the exposure precede the observed adverse pregnancy
747   outcomes? Is there (animal) data on placental transfer?
748   2.       Consistent Findings: Are there consistent findings by multiple epidemiological studies of
749   adequate quality showing a relationship between exposure and adverse pregnancy outcomes? Do other
750   data sources provide further support for concern?
751   3.       Strength of Association: What is the magnitude of the observed association between
752   exposure and adverse pregnancy outcomes as indicated by clinical studies (for a non-interventional
753   study, consider the degree of potential residual confounding)? What is the precision of the estimated
754   association?
755   4.       Specificity of Clinical Phenotype: Is there a specific pattern of defects reported after the
756   exposure? An embryo/fetotoxic substance rarely causes congenital malformations in a wide range of
757   organs. A specific pattern of congenital malformations generally increases the likelihood of a causal
758   relationship.
759   5.       Biological Mechanism: Does the association make biological sense, supported by evidence of
760   a plausible biological mechanism of action, from non-clinical and / or clinical data?
761   6.       Class effects (i.e. analogy): Have similar medicinal products shown similar adverse
762   outcomes, pointing to a class effect that supports a causal relationship, based on non-clinical and / or
763   clinical data?
764   7.       Dose-Response: Is there evidence of a dose-response relationship, indicating that higher
765   exposure levels are associated with greater risks of adverse outcomes?
766   8.       Non-clinical Evidence: Is there evidence of adverse embryo-fetal effects in toxicity studies
767   supporting causality between exposure and adverse pregnancy outcomes? Is the substance genotoxic?
768   9.       Integration and Coherence: Does the overall body of evidence support a coherent and
769   consistent conclusion about a causal relationship between the exposure and adverse pregnancy
770   outcomes?

771   7.1.2.2. Identified risk for adverse pregnancy outcomes

772   The evidence supporting an identified risk may include:

773   •    Study(ies) in humans, with designs and results of sufficient quality to conclude on causality,
774        consistently suggesting an increase in the overall frequency of an adverse pregnancy outcome (or
775        a specific type of an adverse pregnancy outcome). Factors that may be considered include the
776        strength of the association of exposure to the medicinal product in utero with the adverse
777        pregnancy outcome, any evidence of a dose-response relationship, and coherence of the overall
778        body of evidence, as described in the questions in section 7.1.2.1 above.

779   •    Several relevant case-reports, where assessment conclude that a causal relationship between the
780        medicinal product and the adverse pregnancy outcome is at least a reasonable possibility. Factors
781        supporting such relationship include known exposure during the critical period, low frequency of
782        the adverse pregnancy outcome in the general population, specific effect (e.g. an unusual pattern
783        of an adverse pregnancy outcome ), plausible mechanism for the adverse pregnancy outcome in
784        relation to the mechanism of action, known association of other medicinal products in the same
785        class with the adverse pregnancy outcome, and consistency with non-clinical findings of a harmful
786        effect of exposure to the medicinal product in pregnancy.

787   •    Non-clinical data which show a harmful effect(s) after exposure to the medicinal product during
788        gestation, with suspected relevance to humans and with insufficient clinical data;

      Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
      information                                                                                                        Page 21/46
      EMA/CHMP/PRAC/203927/2005 Rev.1

第 22 页

789   •   Mechanism of action with evidence of being a risk for adverse pregnancy outcomes, including
790       known class effects.

791   7.1.2.3. Potential risk for adverse pregnancy outcomes

792   The evidence supporting a potential risk may include:

793   •   Non-clinical data which raise concerns for a harmful effect(s) due to exposure to the medicinal
794       product during gestation, with possible relevance to humans but with insufficient clinical data.

795   •   Mechanism of action which is suspected to adversely interfere with development. This includes
796       possible class effects of risk for adverse pregnancy outcome(s).

797       and/or

798   •   Studies or sources of data such as analysis of human case reports suggesting an increase in the
799       overall frequency of the adverse pregnancy outcome, but insufficient evidence to conclude on
800       causality, due to limitations, inconsistency of findings across data sources, or a lack of other
801       studies or data to corroborate the findings of a single data source. This includes the relevance of
802       the methodology and results of each study and source of data.

803   7.1.2.4. Adverse effects unlikely in humans

804   When a sufficiently large amount of clinical data of adequate quality is available, not raising concerns
805   for adverse pregnancy outcomes, and when knowledge regarding the pharmacological effects of the
806   substance does not raise such concern, it can be concluded that adverse pregnancy effects are
807   unlikely. This would generally correspond to several thousand pregnancies, well documented within a
808   relevant study setting. In this situation, beyond pharmacological data, the non-clinical data have less
809   importance for risk assessment. For some formulations, pharmacokinetic data in humans, showing
810   very low systemic exposure can also support risk assessment.

811   7.1.2.5. Insufficient data with respect to pregnancy

812   For substances where non-clinical data, including knowledge of pharmacological effects, do not raise
813   concerns, but where clinical data are limited, and therefore no firm reassuring conclusions can be
814   drawn. In these situations, available data are considered insufficient.

815   7.1.3. Breastfeeding
816   Following the integrated assessment outlined in section 6, a general risk classification can be applied,
817   based on the available evidence and its strengths and limitations. In all situations below, if the
818   medicinal product is not absorbed from the infant’s gastrointestinal tract, it will not cause systemic
819   effects, but it can still cause local effects in the gastrointestinal tract, such as diarrhoea.

820   7.1.3.1. Identified risk for breastfed infants

821   The evidence supporting an identified risk may include:

822   •   Adverse reactions in breastfed infants in line with the known safety profile and/or the
823       pharmacodynamic effects of the substance.
824   •   Clinically relevant systemic exposure of breastfed infants to the active substance (and/or its
825       metabolites), and/or if the substance (and/or metabolites) is present in significant amounts in
826       breast milk can also support concluding on an identified risk for breastfed infants.

827   7.1.3.2. Potential risk for breastfed infants

828   The evidence supporting a potential risk may include:


      Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
      information                                                                                                        Page 22/46
      EMA/CHMP/PRAC/203927/2005 Rev.1

第 23 页

829   •   Safety profile of a medicinal product including relevant risks, taking pharmacodynamic properties
830       as well as class effects into account, but data on transfer into breastmilk or data on exposure of
831       breastfed infants are lacking. This assessment can in some instances be based on non-clinical data
832       solely, particularly from toxicity testing including peri- and post-natal or juvenile toxicity studies.
833   •   Limited data on milk transfer or of infant exposure suggest levels of the active substance, that may
834       cause adverse effects in the infant.
835   •   Data on milk transfer or infant exposure is not available or limited, but physicochemical properties
836       of active substance, data from a qualified physiologically based pharmacokinetic model using
837       scarce human samples, or from a qualified in vitro method, point to possible high transfer into
838       breast milk.

839   7.1.3.3. Adverse effects unlikely in breastfed infants

840   The evidence supporting that adverse effects are unlikely in breastfed infant may include:

841   •   Sufficient human data from the use in breastfeeding individuals not suggesting a risk, including no
842       reported adverse reactions in the infant.
843   •   Robust data showing that the levels of the substance/metabolites in breastmilk are so low (see
844       section 8.2.1.2) that they are unlikely to pose a concern to the breastfed infant. Alternatively, data
845       may show that the medicinal product does not enter breast milk and/or is not absorbed
846       systemically by the infant.

847   7.1.3.4. Insufficient data with respect to breastfeeding

848   When clinical data from breastfed infants, or on levels in breastmilk are absent or limited, data are
849   considered insufficient. The overall safety profile of the substance does not raise serious concerns.


850   7.2. Principles for recommendations

851   7.2.1. Fertility
852   In most cases, recommendations are not provided in the PI in relation to data on fertility. However, on
853   a case-by-case basis, it may be warranted to include a recommendation into the PI, taking the following
854   into account (see section 8.2.1.3):

855   •   In case of an identified risk of temporarily impaired fertility, a recommendation not to use the
856       medicinal product in males and/or females attempting to conceive, can be considered. Further, in
857       individuals with difficulties conceiving or who are undergoing investigation of infertility, a
858       recommendation to withdraw the treatment can be considered.
859   •   If a risk of irreversible damage of male and/or female gametes has been identified, inclusion of a
860       recommendation seeking counselling for sperm or oocyte preservation before starting treatment,
861       can be considered.


862   7.2.2. Pregnancy

863   The potential risks of in utero exposure to the medicinal product for the developing embryo or fetus
864   (see section 7.1.2), the potential benefits of treatment for the pregnant individual, the risks the
865   untreated condition may pose to both, and alternative treatments, should be taken into account when
866   determining the recommendation for use of the medicinal product in pregnancy. These
867   recommendations should be based on available information from:

868   •   Clinical experience

869   •   Relevant non-clinical studies

      Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
      information                                                                                                        Page 23/46
      EMA/CHMP/PRAC/203927/2005 Rev.1

第 24 页

870   •   Need for treatment

871   7.2.2.1. Clinical experience

872   In case of a potential or an identified risk for serious adverse pregnancy outcomes such as major
873   congenital malformations or NDD (see section 7.1.2), a contraindication to use of the medicinal
874   product in pregnancy, or during defined parts of pregnancy should be considered.

875   A contraindication should also be considered if the medicinal product has a pharmacological profile
876   (mechanism of action) similar to that of a substance or therapeutic class where serious adverse
877   pregnancy outcomes are an identified risk in humans.

878   In cases when available non-clinical and clinical evidence suggests a lower concern for serious adverse
879   pregnancy outcomes, less strict recommendations should be given, taking the need for treatment into
880   account (see section 7.2.2.3).

881   7.2.2.2. Relevant non-clinical studies

882   In some circumstances, a contraindication in humans may be based on non-clinical data only, after a
883   comprehensive assessment of all relevant aspects, such as:

884   •   Pharmacology/mechanism of action: properties known to cause direct or indirect embryo-fetal
885       damage

886   •   Genotoxic potential

887   •   EFD: lethality, congenital malformations, embryo-fetal toxicity including growth retardation, and
888       functional changes, taking the severity of the observed findings, and the exposure level in relation
889       to the human therapeutic exposure into account.

890   7.2.2.3. Need for treatment

891   Where the assessment concludes on an identified or potential risk for adverse pregnancy outcomes,
892   such risk has to be weighed against the potential benefit of the treatment for the pregnant individual,
893   before a recommendation is concluded upon. The following points should be taken into consideration:

894   •   Serious or life-threatening disease, as well as the impact of pregnancy on the disease and the
895       impact of the disease on pregnancy.

896   •   An alternative treatment option, with relevant therapeutic benefit, is available that is safer when
897       used in pregnancy.

898   •   Treatment can be modified, postponed or avoided.

899   A contraindication in pregnancy should only be considered if either, a) safer alternative treatment
900   option is available or, b) treatment can be postponed until after pregnancy.

901   If there is no safer treatment option available and treatment cannot be delayed, the medicinal product
902   should generally not be contraindicated in pregnancy. However, strict recommendations against use in
903   pregnancy and actions to take in case of pregnancy occurring, or if pregnancy is being planned while
904   on treatment, should be included in the SmPC and PL. See also section 8.2.1.

905   7.2.2.4. Recommendations for use during pregnancy

906   Recommendations for use in pregnancy should be based on all relevant evidence, and take the risk
907   classification described in section 7.1.2 into account:




      Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
      information                                                                                                        Page 24/46
      EMA/CHMP/PRAC/203927/2005 Rev.1

第 25 页

908   •   Medicinal product is contraindicated during pregnancy – This applies when an identified or
909       potential risk for serious adverse pregnancy outcome(s) has been concluded upon, and when
910       treatment can be postponed until after pregnancy, or the medical condition can be managed by an
911       alternative treatment option.

912   •   Medicinal product should not be used during pregnancy unless the medical condition
913       requires treatment with {active substance} and cannot be managed by an alternative
914       treatment – This applies when an identified or potential risk for a serious adverse pregnancy
915       outcome(s) is concluded upon, and treatment cannot be postponed until after pregnancy or the
916       medical condition cannot be managed by an alternative treatment option. This also applies when
917       available data are insufficient to draw conclusions about the risk of in utero exposure, but available
918       evidence raises concerns for adverse pregnancy outcomes. This advice can be adapted to meet
919       specific exposure windows when adequately justified.

920   •   Use of the medicinal product may be considered during pregnancy – This applies when data
921       are limited but available evidence does not raise concerns for serious pregnancy outcomes.

922   •   Medicinal product can be used during pregnancy – This applies when the risk assessment of
923       available evidence concludes on an unlikely risk.


924   7.2.3. Individuals of reproductive potential

925   The need for a recommendation for females of reproductive potential to use effective contraception
926   [8,23] to prevent unplanned pregnancy during treatment should be considered when a medicinal
927   product has an identified or potential risk for adverse pregnancy outcomes.

928   Factors that should be taken into account include the robustness of available evidence, the magnitude
929   and severity of identified or potential risk, the target population, and availability of alternative
930   treatment options. Recommendations for females of reproductive potential will also depend on the
931   recommendation with respect to use of the medicinal product in pregnancy.

932   In exceptional cases, for an active substance which can cause serious adverse pregnancy outcomes in
933   human, there can be concerns that the substance can affect embryo-fetal development through
934   transfer to a pregnant individual via seminal fluid from a male individual being treated with the
935   substance [8]. In such situation, a recommendation for male individuals to use a condom if engaged in
936   sexual activity with a pregnant individual or a female of reproductive potential not using effective
937   contraception may be considered.

938   7.2.3.1. Recommendations for use in females of reproductive potential

939   Where the medicinal product is contraindicated in pregnancy (see 7.2.2.4):

940   •   In exceptional circumstances, if a risk of serious embryo-fetal or neonatal harm of larger absolute
941       magnitude has been concluded, the need to prevent exposure to the medicinal product in
942       pregnancy by contraindicating use in females of reproductive potential, unless they are using
943       effective contraception, should be considered.
944   •   In most situations, such contraindication is not warranted. Instead, a recommendation that the
945       medicinal product should not be used in females of reproductive potential unless they are using
946       effective contraception is sufficient.
947   •   In some situations, depending on the indication and the context for use e.g. acute treatments, a
948       recommendation to use effective contraception in females of reproductive potential is not
949       warranted.



      Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
      information                                                                                                        Page 25/46
      EMA/CHMP/PRAC/203927/2005 Rev.1

第 26 页

950   Where the medicinal product should not be used during pregnancy unless the medical condition
951   requires treatment with the active substance and cannot be managed by an alternative treatment (see
952   7.2.2.4):

953   •   When an identified or potential risk for a serious adverse pregnancy outcome(s) is concluded upon,
954       or when available data are insufficient to draw conclusions, but available evidence raises concerns
955       for adverse pregnancy outcomes, a recommendation that females of reproductive potential should
956       use effective contraception should be considered, depending on the potential safety concerns.

957   For all the above situations, there may be circumstances where the possibility for becoming pregnant is
958   very low for a female of reproductive potential. In these circumstances an effective contraception may
959   not be necessary, following discussion with the prescriber. Where such circumstances may change, this
960   should be reviewed regularly.

961   7.2.3.2. Recommendations on risk minimisation measures

962   When the assessment has concluded on an identified risk or a potential risk of serious adverse
963   pregnancy outcomes, concrete measures to avoid or minimise exposure to the medicinal product
964   during pregnancy should be provided in the PI (see section 8 and Annex).

965   Actions to ensure adherence to recommendations in the PI can be combined with additional tools of
966   risk minimisation, including, in exceptional cases, a pregnancy prevention programme (See GVP
967   Module XVI Addendum I – Risk minimisation measures for medicinal products with embryo-fetal risks
968   [24]).


969   7.2.4. Breastfeeding

970   Recommendations for use during breastfeeding should be based on all relevant evidence, including the
971   known benefits of breastfeeding, and take the risk classification described in section 7.1.3 into account.

972   7.2.4.1. Considerations for recommendations in breastfeeding

973   A medicinal product should only be contraindicated during breastfeeding if there exists an identified or
974   potential risk of serious adverse reaction(s) in the breastfed infant. In some circumstances, a potential
975   serious risk can be based on non-clinical or indirect evidence only. Absence of relevant data on
976   breastfeeding alone is not a sufficient reason for a contraindication. The reasons for the (potential or
977   identified) serious risk should be described. If there is concern about a possibility of a potential serious
978   risk for the infant, a recommendation that the medicinal product should not be used during
979   breastfeeding is warranted.

980   If there is a concern about an identified or potential non-serious risk for the infant, a cautionary
981   warning about the use of the medicinal product during breastfeeding should be included, with an
982   explanation provided. This can include that use of the medicinal product during breastfeeding may be
983   considered, with a recommendation to closely observe the breastfed infant (indicating which adverse
984   reactions could be expected) to determine when discontinuation or an interruption of breastfeeding
985   becomes necessary. Alternatively, recommendations on temporary interruption of breastfeeding
986   should be provided, if this is a feasible alternative instead of recommending stopping breastfeeding. In
987   such cases, the duration of interruption should be stated, and the time interval should be estimated
988   based on the half-life of the active substance (and/or active metabolites), oral bioavailability, and
989   safety profile. As a general rule, active substance (and/or metabolites) levels in breast milk are
990   considered negligible after approximately five elimination half-lives [25].




      Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
      information                                                                                                        Page 26/46
      EMA/CHMP/PRAC/203927/2005 Rev.1

第 27 页

991   7.2.4.2. Recommendations for use during breastfeeding

992   Recommendations for use during breastfeeding should be based on all relevant evidence, and take the
993   risk classification described in section 7.1.3 into account:

994   •   Medicinal product is contraindicated during breastfeeding– this applies in case of an
995       identified serious risk or a potential serious risk for the breastfed infant.

996   •   Medicinal product should not be used during breastfeeding– this applies when serious risk
997       for breastfed infant has not been demonstrated but is a possibility.

998   •   Medicinal product may be considered during breastfeeding– this applies when data are limited
999       but available evidence does not raise concerns for serious risk. This includes infant exposure being
1000       unknown or may potentially lead to adverse effects, although a serious risk is not expected.

1001   •   Medicinal product can be used during breastfeeding– this applies when the risk assessment
1002       of available evidence concludes on an unlikely risk.


1003       8. Reflections for the product information

1004   8.1. Introduction

1005   In the SmPC and PL, information regarding male and female fertility, pregnancy and breastfeeding
1006   should include different elements namely:

1007   •   Recommendations with respect to use of the medicinal product in these different populations, as
1008       appropriate.

1009   •   A concise summary of available data concerning use of the medicinal product in these different
1010       populations, including potential and identified risks, impact on relevant outcomes and areas of
1011       uncertainty.

1012   •   Details of recommended actions for risk minimisation to prevent or minimise exposure during
1013       pregnancy, or during breastfeeding, as appropriate, and / or recommendations for females of
1014       reproductive potential, or in some cases, in relation to male fertility.

1015   The overall aim of the wording in the PI is to enable informed and shared decision-making by
1016   healthcare professionals and patients (or individuals and facilitate adherence to risk minimisation
1017   measures.


1018   8.2. Summary of product characteristics (SmPC)

1019   In section 4.6 Fertility, pregnancy and lactation, information and recommendations regarding use in
1020   pregnancy, and breastfeeding, as well as information regarding fertility should always be included.

1021   In some cases, other sections, e.g. section 4.3 Contraindications, 4.4 Warnings and precautions, 4.5
1022   Interactions and section 4.8 Undesirable effects may also complement section 4.6.

1023   Relevant pharmacokinetic data should be reflected in section 5.2 and non-clinical data should be
1024   reflected in section 5.3, including addressing reproductive and developmental effects. In all relevant
1025   cases, cross-references between sections should be added.

1026   If additional risk minimisation tools are implemented (e.g. educational materials for health care
1027   professionals and/or patients), these should generally be referred to in section 4.4 or 4.6 of the SmPC,
1028   and in section 2 of the PL.


       Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
       information                                                                                                        Page 27/46
       EMA/CHMP/PRAC/203927/2005 Rev.1

第 28 页

1029   8.2.1. Section 4.6 of the SmPC

1030   8.2.1.1. Subsection on pregnancy and females of reproductive potential

1031   Clinical data:

1032   Describe the extent of human experience and from which data sources (see sections 5.3 and 7.1.2).
1033   When at least a few hundred prospectively observed exposed pregnancies with known outcomes are
1034   available, it is generally appropriate to detail the numbers of pregnancies, particularly when there are
1035   data from relevant clinical studies (clinical trials or pharmacoepidemiological studies). Where the
1036   number of exposed pregnancies with known outcomes is small (generally less than 100), a more
1037   general description of the data, e.g. being ‘limited’ is more suitable, to reflect data limitations. It will
1038   also avoid small specific numbers becoming rapidly outdated.

1039   If data are sufficiently robust, e.g. results from clinical trials or pharmacoepidemiological studies of
1040   adequate size and quality, the knowledge on main adverse pregnancy outcomes should be
1041   summarised. In case there is a reasonable possibility for a causal relationship between an adverse
1042   pregnancy outcome and exposure, describe:

1043   •   Primary sources of evidence for the observed risk, including (where available) details on pregnancy
1044       exposure (timing, duration), the magnitude of the risk (relative, absolute, and background
1045       frequencies), and the nature of the risk (such as patterns of congenital malformations or NDD and
1046       their severity). Include the comparator used in relevant studies, if applicable.
1047   •   Relevant areas of uncertainty regarding adverse pregnancy outcomes. This may in some
1048       circumstances relate to studies with different results, leading to the overall picture being
1049       inconclusive.

1050   Also, when adequate clinical data provide reassurance regarding use in pregnancy, the primary sources
1051   of evidence, including details on pregnancy exposure (timing, duration), main pregnancy outcomes,
1052   and the comparator used if applicable, should be described. If some uncertainties remain, those should
1053   be summarised shortly.

1054   Non-clinical data:

1055   Only general conclusions of the non-clinical evaluation should be included in section 4.6 of the SmPC.
1056   Further details should be provided in section 5.3 of the SmPC.

1057   Recommendations:

1058   As detailed in sections 7.2.2. and 7.2.3., a recommendation should be included, which generally
1059   ranges from a contraindication in pregnancy and in females of reproductive potential not using
1060   effective contraception, to can be used in pregnancy.

1061   In case measures to minimise or avoid exposure during pregnancy are warranted, those should be
1062   described (see GVP Module XVI Addendum I [24] for further details), including:

1063   •   Risk counselling including the potential risks of using the medicinal product during pregnancy
1064       and the recommendations regarding use during pregnancy.
1065   •   Pregnancy testing to ensure excluding pregnancy before initiating treatment with the medicinal
1066       product (and in exceptional situations during and after treatment discontinuation). Pregnancy
1067       testing would generally be included in the PI as a risk minimisation measure when use in
1068       pregnancy is contraindicated.
1069   •   When effective contraception is recommended, the exact type of contraceptive method should
1070       not be defined, since selection of a contraceptive method should be evaluated individually by the
1071       prescriber and person to be treated. However, in some instances, a medicinal product may impair

       Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
       information                                                                                                        Page 28/46
       EMA/CHMP/PRAC/203927/2005 Rev.1

第 29 页

1072       the effectiveness of some methods of contraception. Such data should be described in the product
1073       information (e.g. section 4.5) and may lead to recommendations on type of contraceptive
1074       methods. Based on the pharmacokinetic properties of the medicinal products, duration of
1075       contraceptive use after stopping treatment should be included in the PI.
1076   •   Actions if a patient considers a pregnancy during treatment or in the event of an unplanned
1077       pregnancy during treatment with the medicinal product. This includes promptly contacting a
1078       healthcare professional to consider the possibility of e.g. interrupting treatment, dose reduction,
1079       switching to an alternative treatment and/ or relevant specific monitoring during pregnancy such
1080       as fetal ultrasound or of the neonate/infant.
1081   •   Consideration to add advice that treatment should be supervised by a physician who is experienced
1082       in the management of the medical condition and the use of the medicinal product, and on regular
1083       medication reviews.
1084   •   Where relevant, consider advice to deter patients from donating blood during and for a specified
1085       period after use of the medicinal product, and/or to deter patients from donating semen during and
1086       for a specified period after use of the medicinal product.

1087   8.2.1.2. Subsection on breastfeeding

1088   All relevant data which are the basis for the recommendation should be shortly described (see also
1089   sections 7.1.3 and 7.2.4). This includes conclusions of pharmacokinetic studies e.g. plasma
1090   concentrations in breastfed infants, concentrations of the active substance and/or its metabolite(s) in
1091   human breast milk (including if it is unknown), calculated relative or daily infant dose. If non-clinical
1092   data are part of the basis for the recommendation, these should be shortly summarised, with reference
1093   to section 5.3 for further details. Estimated absorption from an infant´s gastrointestinal tract should be
1094   reported if relevant.

1095   If possible, quantify the extent of transfer into breastmilk using relative infant dose categories (<2%
1096   minimal, 2–5% low, 5–10% moderate, >10% high) [25] and specify relevant details such as route of
1097   administration and/or dosage strength. If known, the amount relative to a therapeutic infant dose and
1098   infant plasma/blood levels could be mentioned.

1099   Information on known risks in breastfed infants, or long-term clinical experience without observed risks
1100   of specific serious concern, should be included if available.

1101   Other important information should be mentioned, such as large size of molecules possibly precluding
1102   breast milk transfer, lack of oral bioavailability, reminder of safety profile, among others.

1103   The SmPC should describe, when applicable, measures that are intended to minimise exposure of the
1104   breastfed child to the medicinal product and/or its active metabolite(s), such as timing the
1105   administration of the medicinal product relative to breastfeeding and/or short-term interruption of
1106   breastfeeding.

1107   8.2.1.3. Subsection on fertility

1108   The SmPC should describe potential impacts on fertility whenever available evidence indicates that the
1109   medicinal product may impair fertility, including whether temporary or irreversible effects.

1110   Main information on the possible effects of the medicinal product on fertility should be included:

1111   •   Clinical data if available.

1112   •   Relevant conclusions from non-clinical toxicity studies if available. Further details should be
1113       included in Section 5.3 of the SmPC.



       Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
       information                                                                                                        Page 29/46
       EMA/CHMP/PRAC/203927/2005 Rev.1

第 30 页

1114   On a case-by-case basis (see sections 7.1.1 and 7.2.1), it may also be warranted to include advice on
1115   practical considerations e.g., avoiding use in the context of assisted reproductive technology
1116   treatment, for individuals with difficulties conceiving or who are undergoing investigation of infertility,
1117   counselling for gamete preservation or advice not to donate gametes.

1118   Cross-references could be included to other relevant sections of the PI (e.g. section 4.4 of the SmPC),
1119   if appropriate.


1120   8.2.2. Section 4.3 of the SmPC

1121   •   Contraindication in pregnancy (see section 7.2.2.4), or defined parts of pregnancy, with cross-
1122       references to section 4.4 (if considered appropriate) and section 4.6 where further information
1123       about the background to the contraindication as well as all risk minimisation measures should be
1124       provided.

1125   •   Contraindication in females of reproductive potential (see section 7.2.3.1) unless they are using
1126       effective contraception, with cross-references to section 4.4, if considered appropriate and to
1127       section 4.6 where further information about the background to the contraindication should be
1128       provided.

1129   •   Contraindication in breastfeeding (see section 7.2.4.2), with cross-references to section 4.6 where
1130       reasons for contraindication should be explained.


1131   8.2.3. Section 4.4 of the SmPC

1132   If a medicinal product is contraindicated in pregnancy and/ or in females of reproductive potential,
1133   including if a pregnancy prevention programme is implemented (see GVP Module XVI Addendum I
1134   [24]), section 4.4 may shortly state the key risk(s) justifying a contraindication, and shortly focus on
1135   key measures to minimise risk, including pregnancy testing before treatment initiation and use of
1136   contraception, with cross-reference to section 4.3, 4.5 (if applicable) and 4.6, where further details on
1137   the risk as well as on risk minimisation measures should be described.


1138   8.2.4. Section 4.5 of the SmPC

1139   If contraceptive measures are recommended for females of reproductive potential (see section 7.2.3),
1140   relevant information concerning interactions of the medicinal product with methods of contraception
1141   should be addressed, with cross-references to e.g. sections 4.3, 4.4, 4.6 and 5.2.


1142   8.3. Package leaflet (PL)

1143   The package leaflet should reflect all relevant information from the SmPC, and be written in a
1144   comprehensible, lay-person friendly language.

1145   Section 2

1146   Contraindications and precautions for use or special warnings should be included in Section 2 of the PL.

1147   Under Do not take [X]:

1148   •   Contraindication if the patient (or individual) is pregnant (if considered appropriate)
1149   •   Contraindication if the patient (or individual) is a female able to have a child (if considered
1150       appropriate) unless using effective birth control.
1151   •   Contraindication if the patient (or individual) is breastfeeding (if considered appropriate)


       Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
       information                                                                                                        Page 30/46
       EMA/CHMP/PRAC/203927/2005 Rev.1

第 31 页

1152   Under Pregnancy, breastfeeding and fertility:

1153   •   Contraindications or recommendations with respect to use of the medicinal product in pregnant
1154       patients (or individuals), during breastfeeding or in female patients (or individuals who can have a
1155       child.

1156   •   Information on the risks following exposure to the medicinal product in pregnancy, including
1157       (where available):

1158       −    The type of adverse pregnancy outcome, e.g., the pattern of congenital malformations or the
1159            specific type of NDD associated with use of the medicinal product during pregnancy, including
1160            severity.

1161       −    The magnitude of the risk(s) preferably described in absolute terms and in relation to a
1162            relevant comparator. For instance, expressing the number of babies being affected by the
1163            adverse effect among every 100 babies born to individuals taking the medicinal product,
1164            compared with the same figures for babies born to individuals not taking the medicinal product
1165            or for babies born of individuals who do not have the indication for the medicinal product (as
1166            appropriate).

1167   •   If available, information in relation to dose or duration of use.

1168   •   Lack of evidence, and/or reassuring findings, if appropriate.

1169   •   Information on actions to take to prevent exposure to the medicinal product during pregnancy,
1170       during breastfeeding and in an individual who can have a child, in line with recommendations in
1171       the SmPC. Examples on actions to take can be given in the PL as aid to the individual.

1172   •   Information on actions if pregnancy occurs or is considered during treatment, as appropriate, in
1173       line with recommendations in the SmPC.

1174   •   Information on the possible effects following exposure to the medicinal product on male and female
1175       fertility.
1176




       Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
       information                                                                                                        Page 31/46
       EMA/CHMP/PRAC/203927/2005 Rev.1

第 32 页

1177   9.       References
1178   1. ICH E21 Guideline on inclusion of pregnant and breastfeeding individuals in clinical trials
1179        (EMA/CHMP/ICH/149462/2025)
1180   2. ICH S5 (R3) Guideline on detection of reproductive and developmental toxicity for human
1181        pharmaceuticals (EMA/CHMP/ICH/544278/1998)
1182   3. ICH S3A Toxicokinetics: A Guidance for Assessing Systemic Exposure in Toxicology Studies
1183        (CPMP/ICH/384/95 (ICH S3A)).
1184   4. ICH M3(R2) Guideline on non-clinical safety studies for the conduct of human clinical trials and
1185        marketing authorisation for pharmaceuticals (EMA/CPMP/ICH/286/1995)
1186   5. ICH M3 (R2) - questions and answers (EMA/CHMP/ICH/507008/2011)
1187   6. Guideline on non-clinical testing for inadvertent germline transmission of gene transfer vectors
1188        (EMEA/273974/2005)
1189   7. ICH S2 (R1) Guideline on genotoxicity testing and data interpretation for pharmaceuticals intended
1190        for human use (Step 5. 2013) (EMA/CHMP/ICH/126642/2008)
1191   8. Safety Working Party (SWP) / Non-clinical Working Party (NcWP) recommendations on the duration
1192        of contraception following the end of treatment with a genotoxic drug
1193        (EMA/CHMP/SWP/74077/2020)
1194   9. WHO. Guideline for the prevention, diagnosis and treatment of infertility: summary of
1195        recommendations. World Health Organization. (2025).
1196   10. Guideline on good pharmacovigilance practices (GVP): Product- or population-specific
1197        considerations III: Pregnant and breastfeeding women and their children exposed in utero or via
1198        breastmilk (EMA/653036/2019)
1199   11. Euro-Peristat. Live births and stillbirths annual summary statistics 2022, Office for National
1200        Statistics. Available at https://www.europeristat.com/wp-content/uploads/2022/11/Euro-
1201        Peristat_Fact_sheets_2022_for_upload.pdf
1202   12. The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP)
1203        Guide on Methodological Standards in Pharmacoepidemiology. Available at The European Network
1204        of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) Guide on Methodological
1205        Standards in Pharmacoepidemiology - Revision 11
1206   13. ENCePP. Annex 2 to the Guide on Methodological Standards in Pharmacoepidemiology Guidance on
1207        methods for the evaluation of medicines in pregnancy and breastfeeding. Available at Annex 2 to
1208        the Guide on Methodological Standards in Pharmacoepidemiology - Guidance on methods for the
1209        evaluation of medicines in pregnancy and breastfeeding (2nd Edition) (europa.eu)
1210   14. EUROCAT. European Platform on Rare Disease Registration (EU-RD-Platform), European
1211        Commission. Available at https://eu-rd-platform.jrc.ec.europa.eu/eurocat/eurocat-network/jrc-
1212        eurocat-central-registry_en
1213   15. Birth Defects Prevalence — U.S. National Estimates, 2018–2022. Centers for Disease Control and
1214        Prevention (CDC), Available at https://www.cdc.gov/birth-defects/media/pdfs/2026/04/Data-Brief-
1215        Birth-Defects-National-Estimates-2018-2022.pdf
1216   16. ICD-11 for Mortality and Morbidity Statistics. WHO, Available at https://icd.who.int/browse/2024-
1217        01/mms/en#1516623224
1218   17. ICH S6 (R1) Guideline on Preclinical safety evaluation of biotechnology-derived pharmaceuticals
1219        (EMA/CHMP/ICH/731268/1998 (ICH S6)

1220   18. EMA Reflection paper on non-human primates in safety testing of human medicinal products and
1221        opportunities for 3Rs implementation (EMA/CHMP/55697/2025)
1222   19. Guideline on good pharmacovigilance practices (GVP) Module V – Risk management systems (Rev
1223        2) (EMA/838713/2011)


       Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
       information                                                                                                        Page 32/46
       EMA/CHMP/PRAC/203927/2005 Rev.1

第 33 页

1224   20. Rasmussen S, Jamieson D, Honein M, Petersen L. Zika Virus and Birth Defects — Reviewing the
1225       Evidence for Causality. N Engl J Med 2016;374:1981-1987
1226   21. Shepard TH. “Proof” of human teratogenicity. Teratology 1994; 50: 97-8.
1227   22. Frank C, Faber M, Stark K. Causal or not: applying the Bradford Hill aspects of evidence to the
1228       association between Zika virus and microcephaly. EMBO Mol Med 2016 March 1
1229   23. Recommendations related to contraception and pregnancy testing in clinical trials, CTCG Clinical
1230       Trials Coordination Group
1231   24. Guideline on good pharmacovigilance practices (GVP) Module XVI Addendum I – Risk minimisation
1232       measures for medicinal products with embryo-fetal risks (EMA/608947/2021)
1233   25. Hale's Medications & Mothers' Milk 2025-2026: A Manual of Lactational Pharmacology 21st ed.
1234       Edition by Thomas W Hale Rph PhD (Author), Kaytlin Krutsch PhD Pharmd MBA Bcps (Author)
1235




       Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product
       information                                                                                                        Page 33/46
       EMA/CHMP/PRAC/203927/2005 Rev.1

第 34 页

1236       Annex
1237   Standard statements for section 4.6 of Summary of Product Characteristics (SmPC) and section 2 of Package Leaflet (PL):

1238   There are three tables with statements for the SmPC and the PL:

1239   •   Table 1 - Pregnancy and Females of reproductive potential

1240   •   Table 2 – Breastfeeding

1241   •   Table 3 - Fertility.

1242   Tables 1 and 2 are divided into sections for each recommendation of use, ranging from a strict contraindication to that the medicinal product can be used.
1243   For each recommendation in table 1 and 2, there are different statements to be used in describing available data and risk minimisation measures, if
1244   applicable, or other relevant information for the medicinal product, based on the specific assessment (see sections 7 and 8). For fertility, standard
1245   statements to describe data are provided, since in most cases, specific recommendations are not provided in the product information in relation to fertility.
1246   Recommendations may be needed on a case-by-case basis, specifically in situations of identified risk of temporarily impaired fertility, difficulties conceiving
1247   or risk of irreversible damage in fertility (see table 3 and section 7.2.1).

1248   The structure of the product information should be in accordance with the QRD template, i.e. pregnancy, breastfeeding and fertility, with additional sub-
1249   headings in the SmPC and PL, such as “Women of childbearing potential”, “Contraception in males” or “Contraception in females”, as appropriate.
1250   Furthermore, in the QRD template, each subsection starts with description of data, followed by a recommendation and risk minimisation measures, if
1251   applicable.

1252   How to compile the standard statements

1253   SmPC

1254   The assessment of available data for a specific medicinal product, will result in a Recommendation (Section 7.2). This recommendation will be the starting
1255   point for compiling a complete wording for each subpart of section 4.6 of the SmPC. In general, standard wording should be selected from one of the
1256   recommendations only, although it can be adapted if there are no suitable wording for a specific case.

1257   To compile the standard statement, begin with the text in the recommendation-box for the applicable recommendation, and continue adding text following
1258   the steps under the appropriate recommendation (e.g. female of reproductive potential, data description, risk minimisation measures) and include the



       Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product information
       EMA/CHMP/PRAC/203927/2005 Rev.1                                                                                                                         Page 34/46

第 35 页

1259   standard statement that is suitable for the intended medicinal product. If a subsection is irrelevant for the intended medicinal product (e.g. risk minimisation
1260   measures), no standard statement should be included from that specific subsection.

1261   Package leaflet

1262   When compiling the information for the section 2 of the Package leaflet, use the corresponding text in relation to the standard statements used for the
1263   SmPC. In some cases, there are more options in the PL compared to the SmPC standard statements. In such case, use one or several of the PL standard
1264   statements, considering the relevance of the intended product. It is also acceptable to change the order of the selected standard statements, compared to
1265   the order in this Annex, to get a readable text without repetition of information.

1266   Note: {active substance}: there may be cases for which it is most appropriate to use {invented name} i.e.: when the risk depends on the route of
1267   administration or the formulation; N/A – Not applicable. Information is not relevant for the individual (e.g. lack or uncertainty of clinical data, non-clinical
1268   data). No statement should be included in the package leaflet.

1269   Table 1. Pregnancy and females of reproductive potential
           Steps
          drafting                             Template sentences for SmPC                                                        Template sentences for PL section 2
         sentences
                                           Recommendation 1: The medicinal product is contraindicated during pregnancy
                          [Section 4.3] Pregnancy <{trimester} of pregnancy> (see section [Pregnancy] Do not <take><use> this medicine <if you are
                          4.6)                                                            pregnant><during the <first><last> <3 months><6 months> of
                          [Section 4.6] Treatment with {Active substance} is              pregnancy> and <up to {number} weeks <after><before>
                          contraindicated during <pregnancy><the {number} trimester of pregnancy> because it can harm the child.
                          pregnancy> and<up to {number} weeks <after><before>
                          pregnancy> (see section 4.3).

       Step 1. Select recommendation for female of reproductive potential (select one of two options as appropriate to the product and its
       indication)
       Option 1           [Section 4.3] Females of reproductive potential, unless they are                    [Pregnancy] Do not <take> <use> this medicine if you can become
                          using effective contraception.                                                      pregnant, unless you are using effective birth control.
                          [Section 4.6 <section 4.4>] Females of reproductive potential                       [Pregnancy] If you can become pregnant, you must use effective birth
                          must use effective contraception during treatment with {active                      control during treatment with this medicine <and for <at least>
                          substance} and < for {number <days><weeks><months>}>                                {number < days >< weeks><months>} after the last dose of this
                          after treatment>.                                                                   medicine>. You must not become pregnant while <taking><using>
                                                                                                              this medicine.

       Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product information
       EMA/CHMP/PRAC/203927/2005 Rev.1                                                                                                                                       Page 35/46

第 36 页

    Steps
   drafting                             Template sentences for SmPC                                                        Template sentences for PL section 2
  sentences
                   [Section 4.6 <section 4.4>] Individual circumstances should be                      [Pregnancy] Talk to your doctor about birth control methods that may
                   evaluated together with the patient when choosing the                               be right for you. Your doctor will give you information on preventing
                   contraceptive method.                                                               pregnancy and may refer you to a specialist for advice on birth control.
                   There may be individual circumstances where a female is not
                   required to use effective contraception during <and after>
                   treatment with {active substance} following discussion with their
                   prescriber. This should be regularly evaluated to determine
                   whether circumstances change.
Option 2           [Section 4.6] In females of reproductive potential, effective [Pregnancy] If you can become pregnant, effective birth control during
                   contraception during treatment with {active substance} <and < treatment with this medicine <and for <at least> {<number> < days
                   for {<number> < days >< weeks><months>}> after treatment> >< weeks><months>} after the last dose of this medicine> is
                   is recommended.>                                              recommended.
                   [Section 4.6] Individual circumstances should be evaluated                          [Pregnancy] Talk to your doctor about birth control methods that may
                   together with the patient when choosing the contraceptive                           be right for you. Your doctor may refer you to a specialist for advice on
                   method.                                                                             birth control.
Step 2. Select most suitable text describing available data relevant for pregnancy
Clinical data [Section 4.6] Data from {type of study}, including approximately                         [Pregnancy] This medicine may <in <very> rare cases> increase the
               {number} pregnancies, exposed during {Y trimester}, <show >                             risk of <birth defects <such as {list the side effects}><{main adverse
               <suggest > an approximately {number}-fold increase in {main                             pregnancy outcome(s)}> when taken during pregnancy.
      Option 1 adverse pregnancy outcome(s)} corresponding to {concrete
                                                                                                       [Pregnancy] <In pregnant individuals who take {active substance},
               data/numbers; excess risk estimates (if possible); pattern of
                                                                                                       around {number or number interval} children in every {number} will
               {main adverse pregnancy outcome(s)} observed; existence of
                                                                                                       have birth defects. This compares with {number or number interval}
               dose-related effects}, compared with {reference/comparator
                                                                                                       children in every {number} born to individuals who do not have
               group, confidence intervals and background frequency, as
                                                                                                       {condition} and do not take a {medicine class} treatment.>
               applicable}.
       Option 2 [Section 4.6] Based on <human experience {describe type of
                experience shortly}> <and> <or> <mechanism of action>,
                {active substance} <increases> <may increase> the risk of
                embryo-fetal harm when administered during pregnancy.
       Option 3 [Section 4.6] There are no or limited data from the use of {active N/A
                substance} in pregnant individuals.


Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product information
EMA/CHMP/PRAC/203927/2005 Rev.1                                                                                                                                          Page 36/46

第 37 页

    Steps
   drafting                             Template sentences for SmPC                                                        Template sentences for PL section 2
  sentences
Non-clinical       [Section 4.6] Non-clinical data have shown developmental toxicity, N/A
data               including <malformations><embryo-fetal
                   lethality><peri/postnatal mortality> (see section 5.3).
       Option 1
       Option 2 [Section 4.6] Based on non-clinical data <from developmental
                toxicity studies and/or mechanism of action> (see section 5.3)
                {active substance} <increases> <may increase> the risk for
                embryo-fetal harm when administered during pregnancy.
       Option 3 [Section 4.6] Non-clinical data are insufficient with respect to
                developmental toxicity (see section 5.3).
Step 3. Select further risk minimisation measures (<> bracket indicates to select as appropriate to the product, risk and indication)
The alternatives below concern cases where the product is contraindicated in pregnancy and in females of reproductive potential unless they are using
effective contraception, or where the product is contraindicated in pregnancy but not in females of reproductive potential
                                                                                   [Pregnancy] <Read the <select additional risk minimisation material e.g.
                [Section 4.6] <Educational materials for risk minimisation
                measures <select relevant material e.g. checklist, guide> are      patient guide, patient card> <that you will receive from your
                available for <health care professional> <patients > <and          <doctor><pharmacist> <find in the package> >
                   caregivers>. The patient <select additional risk minimisation
                   material e.g. patient guide or patient card> must be provided to
                   <select target group e.g. females of reproductive potential >.
<Pregnancy         [Section 4.6 <section 4.4>] In females of reproductive potential, [Pregnancy] If you can become pregnant, you must take a pregnancy
testing>           a pregnancy test must be negative before the start of treatment test that must be negative before starting treatment with this
                   with {active substance}.                                          medicine.
<Counselling [Section 4.6 <section 4.4>] Females of reproductive potential                             [Pregnancy] Talk to your doctor about the risks of <taking><using>
>            must be advised about the risks of using {active substance}                               this medicine during pregnancy for advice on <appropriate actions to
             during pregnancy and about the risk minimisation measures to                              avoid becoming pregnant><and><or><birth control methods >, if you
             avoid use during pregnancy, including contraceptive measures.                             can become pregnant.
<When              [Section 4.6 <section 4.4>] If a female using {active substance}                    [Pregnancy] If you are planning to become pregnant during the use of
pregnancy is       plans to become pregnant, treatment must be discontinued <,                         this medicine, treatment with this medicine must be stopped<, and, if
considered         and, if needed, switched to an alternative treatment> before                        needed, switch to another medicine> before stopping birth control.
during             contraception is discontinued. To facilitate this,                                  <Your doctor will discuss with you your treatment needs and suitable
treatment>                                                                                             treatment alternatives.>Do not stop <taking><using> your birth
                                                                                                       control before you have discussed it with your doctor.

Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product information
EMA/CHMP/PRAC/203927/2005 Rev.1                                                                                                                                       Page 37/46

第 38 页

    Steps
   drafting                             Template sentences for SmPC                                                        Template sentences for PL section 2
  sentences
                   -<the female should be advised to consult her physician as soon                     [Pregnancy] <Talk to your doctor <or to a specialist experienced in
                   as she is planning pregnancy>.                                                      {the indication for the product}> as soon as you plan to become
                                                                                                       pregnant during treatment with this medicine.>
                   -<a specialist experienced in the management of {the indication
                   for the product} must be consulted>.
<Unplanned [Section 4.6 <section 4.4>] If an individual becomes pregnant                               [Pregnancy] If you discover that you are pregnant while
pregnancy  while using {active substance}:                                                             <taking><using> this medicine,
during
           -<the individual should be advised to urgently consult the                                  - <talk to your doctor immediately for advice. Do not delay seeking
treatment>
           physician>.                                                                                 medical guidance.>
                   -<the individual should be advised to immediately cease                             - <do not stop <taking><using> this medicine on your own, as your
                   treatment with {active substance}.>                                                 condition may become worse.>
                   -<the individual must be immediately referred to a specialist to                    - <your doctor can tell you to stop treatment immediately>
                   re-evaluate treatment with {active substance} and consider
                   alternative options>.                                                               - <your doctor will urgently refer you to a specialist experienced in
                                                                                                       treating {the indication for the product}. The specialist will reassess
                   The individual should be evaluated and counselled regarding the                     your treatment and consider another medicine for you.>
                   exposed pregnancy.
                                                                                                       - <you may also get advice about the possible effects of this medicine
                                                                                                       on your pregnancy and your treatment options.>
  Recommendation 2: Medicinal product should not be used during pregnancy unless medical condition requires treatment and cannot be
                                                  managed by an alternative treatment.
                                                                        [Pregnancy] You should not <take><use> this medicine <if you are
           [Section 4.6] {Active substance} should not be used during
                                                                        pregnant><during the {number} trimester of pregnancy><up to
           <pregnancy>< the {number} trimester><up to {number} weeks
                                                                        {number} weeks <after><before> treatment> unless considered
           <after><before> treatment> unless the medical condition
                                                                        necessary for treating your condition, and any other treatment is not
           requires treatment with {active substance} and cannot be
                                                                        suitable.
           managed by an alternative treatment.
Step 1. Select recommendation for female of reproductive potential (select one of two options as appropriate to the product and its
indication)
Option 1           [Section 4.6] In females of reproductive potential, effective                       [Pregnancy] If you can become pregnant, effective birth control during
                   contraception should be used during treatment with {active                          treatment with this medicine <and for <at least> {<number> <days
                   substance} and <for {number} < days ><                                              >< weeks><months>} after the last dose of this medicine> is
                   weeks><months>><after treatment>>                                                   recommended.


Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product information
EMA/CHMP/PRAC/203927/2005 Rev.1                                                                                                                                           Page 38/46

第 39 页

    Steps
   drafting                             Template sentences for SmPC                                                        Template sentences for PL section 2
  sentences
                   [Section 4.6] Individual circumstances should be evaluated                          [Pregnancy] Talk to your doctor about birth control methods that may
                   together with the patient when choosing the contraceptive                           be right for you. Your doctor will give you information on preventing
                   method.                                                                             pregnancy and may refer you to a specialist for advice on birth control.
Option 2           [Section 4.6] No recommendation for females of reproductive                         N/A
                   potential is warranted
Step 2. Select most suitable text describing available data
Clinical data [Section 4.6] Data from {type of study}, including approximately [Pregnancy] <In <very> rare cases>, this medicine may increase the
               {number} pregnancies, exposed during {Y trimester}, <show > risk of <birth defects <such as {list the side effects}>>< {main
               <suggest > an approximately {number}-fold increase in {main     adverse pregnancy outcome(s)}> when taken during pregnancy.
      Option 1 adverse pregnancy outcome(s)} corresponding to {concrete
               data/numbers; excess risk estimates (if possible); pattern of
               {main adverse pregnancy outcome(s)} observed; existence of
               dose-related effects}, compared with {reference/comparator
               group, confidence intervals and background frequency, as
               applicable}.
       Option 2 [Section 4.6] Based on <human experience {describe type of
                experience shortly}> <and> <or> <mechanism of action>,
                {active substance} <increases> <may increase> the risk of
                embryo-fetal harm when administered during pregnancy.
       Option 3 [Section 4.6] There are no or limited data from the use of {active N/A
                substance} in pregnant individuals.
Non-clinical       [Section 4.6] Non-clinical data have sown developmental toxicity, N/A
data               including <malformations><embryo-fetal
                   lethality><peri/postnatal mortality> (see section 5.3).
       Option 1
       Option 2 [Section 4.6] Based on non-clinical data <from developmental
                toxicity studies and/or mechanism of action> (see section 5.3)
                {active substance} <increases> <may increase> the risk for
                embryo-fetal harm when administered during pregnancy.
       Option 3 [Section 4.6] Non-clinical data are insufficient with respect to
                developmental toxicity (see section 5.3).


Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product information
EMA/CHMP/PRAC/203927/2005 Rev.1                                                                                                                                          Page 39/46

第 40 页

    Steps
   drafting                             Template sentences for SmPC                                                        Template sentences for PL section 2
  sentences
       Option 4 [Section 4.6] Non-clinical data do not indicate developmental
                toxicity (see section 5.3).
Step 3. Select further risk minimisation measures (<> bracket indicates to select as appropriate to the product, risk and indication)
<Pregnancy         [Section 4.6 <section 4.4>] <In females of reproductive potential, [Pregnancy] <If you can become pregnant, you should considering take
testing>           a pregnancy test should be considered before starting treatment.> a pregnancy test before starting treatment with this medicine.>

<Counselling [Section 4.6 <section 4.4>] Females of reproductive potential  [Pregnancy] Your doctor should tell you about risks of
>            must be advised about the risks of using {active substance}    <taking><using> this medicine during pregnancy and should advice
             during pregnancy and about the risk minimisation measures to   you about use during pregnancy, if you can become pregnant.
             avoid use during pregnancy <including contraceptive measures>.
<When              [Section 4.6 <section 4.4>] If an individual using {active           [Pregnancy] If you are planning to become pregnant during the use of
pregnancy is       substance} plans to become pregnant, treatment may need to be this medicine, treatment with this medicine may need to be stopped <,
considered         discontinued <, and, if needed, switched to an alternative           and, if needed, switched to another medicine> before stopping birth
during             treatment> before contraception is discontinued. To facilitate this, control. < Your doctor will discuss with you your treatment needs and
treatment>                                                                              suitable treatment alternatives.> Do not stop <taking><using> your
                   -<the individual should be advised to consult the physician as
                                                                                        birth control method before you have discussed it with your doctor.
                   soon as planning pregnancy>.
                                                                                        [Pregnancy] <Talk to your doctor <or to a specialist experienced in
                   -<a specialist experienced in the management of {the indication
                                                                                        {the indication for the product}> as soon as you plan to become
                   for the product} may be consulted>.
                                                                                        pregnant.>
                                                                                                       [Pregnancy] <Discuss <with your doctor> whether <taking><using>
                                                                                                       this medicine during pregnancy is suitable for you, considering your
                                                                                                       treatment needs and any potential side effects to the child. The doctor
                                                                                                       may suggest switching to another medicine.>
<Unplanned [Section 4.6 <section 4.4>] If an individual becomes pregnant                               [Pregnancy] If you discover that you are pregnant while taking this
pregnancy  while using {active substance}:                                                             medicine,
during
           -<the individual should be advised to urgently consult the                                  - <talk to your doctor immediately for advice. Do not delay seeking
treatment>
           physician>.                                                                                 medical guidance.>
                   -<the individual should be advised to immediately cease                             - <do not stop <taking><using> this medicine on you own, as your
                   treatment with {active substance}.>                                                 condition may become worse. >
                                                                                                       - <your doctor may tell you to stop treatment immediately>


Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product information
EMA/CHMP/PRAC/203927/2005 Rev.1                                                                                                                                         Page 40/46

第 41 页

    Steps
   drafting                             Template sentences for SmPC                                                        Template sentences for PL section 2
  sentences
                   -<the individual must be immediately referred to a specialist to                    -<your doctor will urgently refer you to a specialist experienced in
                   re-evaluate treatment with {active substance} and consider                          treating {the indication for the product}. The specialist will reassess
                   alternative options>.                                                               your treatment and consider another medicine for you.
                   The individual should be referred for evaluation and counselling                    [Pregnancy] < Discuss <with your doctor> whether <taking><using>
                   regarding the exposed pregnancy.                                                    this medicine during pregnancy is suitable for you, considering your
                                                                                                       treatment needs and any potential side effects to the child. The doctor
                                                                                                       may suggest switching to another medicine.>
                                Recommendation 3: Use of the medicinal product during pregnancy may be considered
                                                                                 [Pregnancy] Discuss with your doctor whether this medicine is right for
                   [Section 4.6] The use of {active substance} may be considered
                   <during pregnancy><during the {number} trimester of           you during pregnancy, considering your treatment needs and any
                   pregnancy>.                                                   potential side effects to the child

Step 1. Select most suitable text describing available data
Clinical data [Section 4.6] Data from {type of study}, including approximately [Pregnancy] The effects of this medicine on a child are yet not clear,
               {number} pregnancies, exposed during {number} trimester, do but current knowledge suggests that there is no risk to the child.
      Option 1
               not suggest an increased risk of adverse pregnancy outcomes;
                                                                                  [Pregnancy] Use of this medicine may therefore be considered <during
               however, available data are insufficient to draw firm conclusions.
                                                                                  pregnancy><during the <first><last> <3 months><6 months> of
                                                                                  pregnancy><up to {number} weeks <after><before> treatment>.
       Option 2 [Section 4.6] There are no or limited data from the use of {active N/A
                substance} in pregnant individuals.
Non-clinical       [Section 4.6] Non-clinical data are insufficient with respect to                    N/A
data               developmental toxicity (see section 5.3).
       Option 1
       Option 2 [Section 4.6] Non-clinical data have shown developmental toxicity
                not considered clinically relevant (see section 5.3).
       Option 3 [Section 4.6] Non-clinical data do not indicate developmental
                toxicity (see section 5.3).
                                                Recommendation 4: Medicinal product can be used during pregnancy



Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product information
EMA/CHMP/PRAC/203927/2005 Rev.1                                                                                                                                           Page 41/46

第 42 页

           Steps
          drafting                             Template sentences for SmPC                                                        Template sentences for PL section 2
         sentences
                                                                                                              [Pregnancy] You can use this medicine during <pregnancy> <the
                          [Section 4.6] {Active substance} can be used <during
                          pregnancy><during {trimester} of pregnancy >                                        <first><last><3 months><6 months> of pregnancy>.

       Step 1. Select most suitable text describing available data
       Clinical data [Section 4.6] Data from {type of study}, including approximately N/A
                      {number} pregnancies, exposed during {number trimester}, do
             Option 1
                      not indicate an increased risk of {main adverse pregnancy
                      outcome(s)}, based on {brief summary of findings}.

              Option 2 [Section 4.6] A large amount of data from pregnant individuals
                       {approximate number} indicates no increased risk of adverse
                       embryo-fetal or neonatal effects.
              Option 3 [Section 4.6] No effects are anticipated during pregnancy since
                       systemic exposure to {active substance} is negligible.


1270   Table 2. Breastfeeding
            Steps
           drafting                             Template sentences for SmPC                                                       Template sentences for PL section 2
          sentences
                                             Recommendation 1: The medicinal product is contraindicated during breastfeeding
                            [Section 4.3] Breastfeeding (see section 4.6).                                    [Do not <take> <use> X] If you are breastfeeding.
                                                                                                              [Breastfeeding] Do not breastfeed during treatment with this medicine.
                            [Section 4.6] {Active substance} is contraindicated during
                            breastfeeding (see section 4.3). Breastfeeding must be                            You must stop breastfeeding before treatment with this medicine.
                            discontinued during treatment with {active substance}.
        Step 1. Select most suitable text describing available data
                        [Section 4.6] <{Active substance} <metabolites> have been                               [Breastfeeding] <This medicine passes into breast milk in high
        Clinical data
                        detected in human breast milk in high amount. Serious                                   amounts that reach the breastfed child. Serious side effects <such as
             Option 1 adverse reactions <such as {give examples of reported                                     {give examples of reported side effects}> have been reported in
                        adverse reactions}> have been reported in breastfed infants of                          breastfed children whose mothers used <invented name>.>
                        treated mothers.>                                                                       <Although this medicine passes into breast milk in low amounts,
                        <Although {Active substance} <metabolites> have been                                    serious side effects <such as {give examples of reported side
                        detected in human breast milk in low amount, serious adverse

       Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product information
       EMA/CHMP/PRAC/203927/2005 Rev.1                                                                                                                                         Page 42/46

第 43 页

     Steps
    drafting                             Template sentences for SmPC                                                       Template sentences for PL section 2
   sentences
                      reactions <such as {give examples of reported adverse                              effects}> have been reported in breastfed children whose mothers
                      reactions}> have been reported in breastfed infants of treated                     used <invented name>.>
                      mothers.>                                                                          [Breastfeeding] <This medicine passes into breast milk and is likely
                      <{Active substance} <metabolites> are excreted into human                          to cause serious side effects <such as {give examples of reported
                      milk to such an extent that serious adverse reactions in the                       side effects}> in a breastfed child.>
                      breastfed infant are likely.>
                      [Section 4.6] <Physicochemical data suggest excretion of
        Option 2
                      {active substance} <metabolites> in breast milk><which
                      could lead to clinically relevant systemic exposure of the
                      breastfed infant >.>
                      <Serious adverse reactions in the breastfed infant are likely>.
                                         Recommendation 2: Medicinal product should not be used during breastfeeding
                     [Section 4.6] {Active substance} should not be used during                        [Breastfeeding] <This medicine should not be used during
                     breastfeeding.[OR] <Breastfeeding should be discontinued                          breastfeeding.> <You should stop breastfeeding before treatment with
                     during treatment with {active substance}>                                         this medicine.>
                                                                                                       [Breastfeeding] Do not breastfeed during treatment with this medicine.
                                                                                                       You must stop breastfeeding before treatment with this medicine.

Step 1. Select most suitable text describing available data
                 [Section 4.6] <{Active substance} <metabolites> have been                               [Breastfeeding] <This medicine passes into breast milk
Clinical data
                 detected in human breast milk in <minimal> <low> <high>                                 <minimal><low><high> amounts and reaches the breastfed child.
      Option 1 amount. Adverse reactions <such as {give examples of                                      Side effects <such give examples of reported side effects}> have
                 reported adverse reactions}> have been reported in breastfed                            been reported in breastfed children whose mothers used this
                 infants of treated mothers.>                                                            medicine.>
                 <{Active substance} <metabolites> are excreted into human                               <This medicine passes into breast milk and is possible to cause side
                 milk to such an extent that adverse reactions on the breastfed                          effects <such as {give examples of reported side effects}> in the
                 infant are possible.>                                                                   breastfed child.>
                 [Section 4.6] <Physicochemical data suggest excretion of
      Option 2
                 {active substance} <metabolites> in breast milk><which
                 could lead to clinically relevant systemic exposure of the
                 breastfed infant.>
                 <Adverse reactions in the breastfed infant are possible.>
                 [Section 4.6] It is unknown whether {active substance}                                  N/A
  Non-clinical
                 <metabolites> are excreted in human milk. Non-clinical data
           data
                 have shown toxicity <from developmental toxicity studies

Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product information
EMA/CHMP/PRAC/203927/2005 Rev.1                                                                                                                                          Page 43/46

第 44 页

     Steps
    drafting                             Template sentences for SmPC                                                       Template sentences for PL section 2
   sentences
                      and/or mechanism of action><such as {concrete adverse
        Option 1
                      effects}> (see section 5.3).


                                 Recommendation 3: Use of the medicinal product during breastfeeding may be considered
                     [Section 4.6] The use of {active substance} may be considered                     [Breastfeeding] Discuss with your doctor whether this medicine is right
                     during breastfeeding. A decision whether to breastfeed while                      for you while breastfeeding, considering the benefits of breastfeeding
                     using {active substance} should take into account both the                        and any potential side effects for your child.
                     benefit of breastfeeding and the potential risk of adverse
                     reactions in the infant.
Step 1. Select most suitable text describing available data
                 [Section 4.6] <It is unknown whether {active substance}                                 [Breastfeeding] <It is unknown if this medicine passes into the
Clinical data
                 <metabolites> are excreted in human milk.>                                              breast milk.>
      Option 1 Alternatively: < {active substance} <metabolites> are                                     Alternatively: <This medicine passes into the breast milk in low
                 excreted in human milk in low levels.>                                                  amounts.>
                 <Serious adverse reactions on a breastfed infant are not                                <Serious side effects in the breastfed child are not expected.>
                 expected>
                 [Section 4.6] <{Active substance} is not expected to be                                 [Breastfeeding] < This medicine passes into breast milk, however, it
      Option 2
                 absorbed from infant´s gastrointestinal tract.>                                         is not expected to pass from your child's stomach and intestines into
                                                                                                         their blood stream.>
                      [Section 4.6] <Physicochemical data suggest excretion of                           [Breastfeeding] <This medicine may pass into the breast milk.>
        Option 3
                      {active substance} <metabolites> in breast milk><which                             <Serious side effects in the breastfed child are not expected.>
                      could lead to clinically relevant systemic exposure of the                         Breastfeeding may be considered while you are <taking><using>
                      breastfed infant>                                                                  this medicine.
                      <Serious adverse reactions on a breastfed infant are not
                      expected>.
                                              Recommendation 4: Medicinal product can be used during breastfeeding
                     [Section 4.6] {Active substance} can be used during                               [Breastfeeding] You can use this medicine while breastfeeding.
                     breastfeeding.
Step 1. Select most suitable text describing available data
                      [Section 4.6] <No effects of {active substance} have been                          [Breastfeeding] <No side effects have been shown in breastfed
Clinical data
                      shown in breastfed infants of treated mothers.>                                    children whose mothers <used><received> this medicine.>
        Option 1

Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product information
EMA/CHMP/PRAC/203927/2005 Rev.1                                                                                                                                             Page 44/46

第 45 页

     Steps
    drafting                             Template sentences for SmPC                                                       Template sentences for PL section 2
   sentences
                      [Section 4.6] <No effects on the breastfed infant are                              [Breastfeeding] <Side effects in the breastfed child are not
        Option 2
                      anticipated since the systemic exposure of {active substance}                      anticipated.>
                      on the breastfed infant is negligible.>
                      [Section 4.6] <{Active substance} <metabolites> are                                [Breastfeeding] <Serious side effects in the breastfed child are
        Option 3
                      excreted in human milk, but at therapeutic doses of {active                        unlikely.>
                      substance} no effects on the breastfed infant are anticipated.>
                      <Serious adverse reactions on the breastfed infant are
                      unlikely.>
                                                Breastfeeding recommendations for specific medicinal products
Monoclonal           [Section 4.6] <It is unknown whether {active substance} is       [Breastfeeding] <It is not known whether this medicine passes into
antibodies           excreted in human breast milk. Human IgGs are known to be        breast milk. Some natural antibodies (a type of protein) pass into
                      excreted in breast milk for a few days after birth, declining to breast milk for a few days after birth, but their levels drop quickly
                      low levels thereafter. Therefore, exposure of the breastfed      after this time. Because of this, a possible risk to a breastfeeding
                      infant <and a risk for adverse reactions> is possible during the newborn during those first few days after birth cannot be fully ruled
                      initial days after birth.>                                       out. >
                      [Considering the major elements of assessment, the following
                      sentence may also be included]                                   [breastfeeding] <After the first few days, breastfeeding may be
                      [Breastfeeding] <Beyond this period, use of {active              considered>
                      substance} during breastfeeding may be considered.>
                                                                                       [Breastfeeding] <Talk to your doctor about whether to use this
                                                                                       medicine while breastfeeding, considering the benefits of
                                                                                       breastfeeding, your treatment needs, and the potential risks of side
                                                                                       effects to your child.>
Protein-             [Section 4.6] <It is unknown whether {active substance} is       [Breastfeeding] <It is not known whether this medicine passes into
based                excreted in human breast milk. However, protein-based            breast milk. However, medicines made from proteins are expected to
therapeutics         products are expected to be denatured and degraded in the        be broken down in the child’s body and are unlikely to affect the
                      infant’s gastrointestinal tract.>                                child.
                      [Considering the major elements of assessment, the following     Because of this, breastfeeding can be considered while you are
                      sentence may also be included]                                   <taking><using> this medicine.>
                      [Breastfeeding] < Use of {active substance} during
                                                                                       <Talk to r your doctor to discuss if you should use this medicine
                      breastfeeding may be considered.>
                                                                                       while breastfeeding, considering the benefits of breastfeeding, your
                                                                                       treatment needs, and the potential risks of side effects to your
                                                                                       child.>




Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product information
EMA/CHMP/PRAC/203927/2005 Rev.1                                                                                                                                             Page 45/46

第 46 页

1271   Table 3. Fertility
           Steps
          drafting                             Template sentences for SmPC                                                        Template sentences for PL section 2
         sentences
        Step 1. Select most suitable text describing available data
                        [Section 4.6] <Based on the mechanism of action of {active                              There is a risk that this medicine <temporarily><permanently>
        Clinical data
                        substance}, there is a risk for impaired fertility in                                   affects your ability to <get pregnant><father a child>.
             Option 1 <both><males> <and> <or> <females>.>
                                                                                                                <Discuss with your doctor before you <take><use> this medicine if
                              [Section 4.6] <Clinical data <show> <suggest> risk of                             you are planning to have a child.>
               Option 2
                              <reversible><irreversible> <impaired fertility> after
                              treatment with {active substance} in <both><males> <and>
                              <or> <females>.
                              [Section 4.6] <There is no human data with respect to
               Option 3                                                                                         No statement needed
                              fertility.>
                              [Section 4.6] <Non-clinical data with {active substance} have                     There is a risk that this medicine <temporarily><permanently>
        Non-clinical
                              shown <reversible> <irreversible> adverse effects on fertility                    affects your ability to <get pregnant><father a child>.
        data
                              in <both><males> <and> <or> <females> (see section
                                                                                                                <Discuss with your doctor before you <take><use> this medicine if
               Option 1       5.3).>
                                                                                                                you are planning to have a child.>
                              [Section 4.6] <Findings from non-clinical data indicate that
               Option 2                                                                                         N/A
                              {active substance} may impair <both><males> <and> <or>
                              <females> fertility (see section 5.3).>


                              [Section 4.6] <Fertility studies with {active substance} were
               Option 3
                              not performed in animals.>
                              [Section 4.6] < Findings from non-clinical data with {active
               Option 4
                              substance} are inconclusive on <both><males> <and> <or>
                              <females> fertility (see section 5.3).>
                              [Section 4.6] <Non-clinical data with {active substance}
               Option 5
                              <have not shown><do not suggest> any adverse effects on
                              fertility in <both><males> <and> <or> <females>> (see
                              section 5.3).
1272



       Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product information
       EMA/CHMP/PRAC/203927/2005 Rev.1                                                                                                                                      Page 46/46

来源:EMA Scientific Guidelines · ema.europa.eu